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 Inhibitor of DNA binding/differentiation protein 4 (ID4) is a dominant negative 
regulator of basic helix loop helix (bHLH) family of transcription factors. ID4 shares the 
homology of HLH domain with other ID proteins (ID1, ID2, and ID3) and lack the basic 
DNA binding region. Evidence suggested that unlike ID1, ID2 and ID3, ID4 acts as a 
tumor suppressor in prostate cancer by attenuating cell proliferation and promoting 
apoptosis. Consistent with these observations ID4 is epigenetically silenced in DU145 
prostate cancer cell line. In this study we investigated whether ID4 is also epigenetically 
silenced in prostate cancer. We also examined association between ID4 promoter hyper-
methylation and its expression in prostate cancer cell lines. ID4 protein expression was 
analyzed in human prostate adenocarcinoma samples by Immunohistochemistry (IHC). 
ID4 promoter methylation pattern on prostate cancer cell lines was examined by 
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methylation specific PCR. In addition, we performed methylation specific PCR on the 
human prostate tissues and genomic DNA to correlate cell line studies with clinical 
studies.  IHC demonstrated decreased ID4 protein expression in human prostate tissue 
samples, whereas higher nuclear ID4 expression was found in normal prostate tissues. 
ID4 methylation specific PCR (MSP) on prostate cancer cell lines, showed ID4 
methylation in DU145, but not in LNCaP and C33 cells. C81 and PC3 cells showed 
partial methylation. Increased ID4 methylation in C81 as compared to LNCaP suggests 
its epigenetic silencing as cells acquire androgen independence. Tumors with ID4 
promoter hyper-methylation showed distinct loss of ID4 expression. However, the 
underlying mechanism involved in epigenetic silencing of ID4 is currently unknown.  We 
hypothesized that ID4 promoter methylation is initiated by an EZH2 dependent tri-
methylation of histone 3 at lysine 27 (H3K27Me3). ID4 expressing (LNCaP) and non-
expressing (DU145 and C81) prostate cancer cell lines were used to investigate EZH2, 
H3K27Me3 and DNMT1 enrichment on ID4 promoter by Chromatin immuno-
precipitation (ChIP). Increased enrichment of EZH2, H3K27Me3 and DNMT1 in DU145 
and C81 cell lines was compared to ID4 expressing LNCaP cell line. Knockdown of 
EZH2 in DU145 cell line led to re-expression of ID4 and decrease in enrichment of 
EZH2, H3K27Me3 and DNMT1 demonstrating that ID4 is regulated in an EZH2 
dependent manner. ChIP on prostate cancer tissue specimens and cell lines suggested 
EZH2 occupancy and H3K27Me3 marks on the ID4 promoter. Collectively, our data 
indicate a PRC2 dependent mechanism in ID4 promoter silencing in prostate cancer 
through recruitment of EZH2 and a corresponding increase in H3K27Me3. Increased 
EZH2, but decreased ID4 expression in prostate cancer strongly supports this model.
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 The basic helix-loop-helix (bHLH) proteins form a large super-family of 
transcription factors that regulate tissue-specific transcription (1). Members of this family 
have two highly conserved domains: the carboxyl terminal end of bHLH contains the 
helix loop helix (HLH) domain involved in forming a homo or hetero-dimer with other 
bHLH proteins and the amino terminal end contains the basic domain that binds to DNA 
sequences called E-box (CANNTG) (2). bHLH proteins play important role in many 
physiological processes including cellular differentiation, apoptosis, cell cycle arrest and 
regulate critical developmental processes (3). The four inhibitors of DNA-binding (ID) 
proteins, ID1–4 are negative regulators of basic bHLH transcription factors.  Structurally, 
the core HLH domain between ID and bHLH proteins is highly conserved that allows 
efficient ID-bHLH dimerization. However, the ID-bHLH dimer is transcriptionally 
inactive due to the lack of DNA-binding basic domain in ID proteins (4). Therefore, the 
interference of ID proteins with the key regulatory bHLH proteins is an important 
interaction that determines for proliferation versus differentiation. 
The repertoire of ID regulated cellular pathways is large and diverse due to their 
ability to interact and modulate the activity of bHLH and non-bHLH transcription factors 




As key regulators of cell cycle and differentiation, ID proteins have shown a vast 
regulatory function across diverse cellular functions, including cell cycle, apoptosis, 
senescence and cancer (6). 
In general, the expression of ID proteins (ID1-ID3) is high in proliferating cells 
(7, 8). Their expression is down regulated during differentiation (9). Consistent with 
these observations the expression of ID1, ID2 and ID3 proteins is increasingly observed 
in many cancers and, in most cases, associated with aggressiveness of the disease 
including poor prognosis, metastasis, and angiogenesis (10, 11). In contrast, the 
expression of ID4 decreases in many cancers (12). Of all the four ID proteins, the 
underlying mechanism of ID1, ID2 and, to a lesser extent, ID3 in cancer is relatively well 
known (2). ID1, ID2 and ID3 have been shown to negatively regulate the expression of 
Cyclin D1, p16 and p21, but promote the expression of matrix metalloproteinase (MMPs) 
(13-15) and thus, promote aggressiveness of disease. On the contrary, large numbers of 
studies have reported reduced ID4 expression due to promoter hyper-methylation during 
cancer progression to a more malignant phenotype (2, 4). 
ID4 is required for normal prostate morphogenesis where it is specifically 
expressed in the luminal epithelial cells (16). Prostates from Id4-/- mice exhibit decreased 
branching morphogenesis and often display prostatic intra-epithelial neoplastic lesions 
(PIN) (16). Loss of ID4 expression is also frequently observed in prostate cancer, 
suggesting its essential role as a tumor suppressor (4, 17). Knockdown of ID4 in LNCaP 
prostate cancer cell lines results in aggressive growth, increased cell survival and 




(18). In addition to prostate cancer, decreased ID4 expression is also observed in 
leukemia (19), AML (20-24), CLL (25), ALL (26), glial neoplasia (27), squamous cell 
carcinoma (28), gastric cancer (29), pancreatic cancer (30), colorectal adenocarcinoma 
(31, 32), malignant lymphoma (33), cholangiocarcinoma (34), Barrett's esophagus and 
esophageal adenocarcinoma (35) and lung cancer (36) (Table 1). Thus, epigenetic 
inactivation of ID4 due to promoter methylation appears to be the key mechanism in 
many cancers. 
Table 1: Role of ID4 in development and other cancers                            
Tumor Suppressor Oncogene Development 





CLL Glioblastoma Prostate 
ALL Breast Brain 
Glial Neoplasia 
  























DNA methylation is a complex series of epigenetic re-programming events which 
involves precise interaction of a multitude of chromatin proteins including assembly of 
polycomb repressive complex 2 and 1 (PRC1/PRC2) (37). Enhancer of Zeste 2 (EZH2) is 
part of the Polycomb repressor complex 2 (PRC2) that also includes SUZ12 (suppressor 
of Zeste 2) and EED (embryonic ectoderm development). Together, the PRC2 complex is 
involved in epigenetic re-programming in both normal and disease states including 
cancer (38).  As a histone methyltransferase, EZH2 is specifically involved in covalent 
modification of histone tails, specifically tri-methylation (Me3) of lysine 27 (K27) on 
histone 3 (H3) (H3K27Me3), a repressive mark found on many gene promoters that are 
silenced (39). EZH2, as part of the PRC2 complex also recruits DNMTs (DNA methyl 
transferases) that, in turn, promotes DNA methylation at CpG islands (CGI) thus, 
connecting the two key epigenetic repression systems (40). EZH2 plays a critical role in 
cell fate determination and its increased expression is observed in many cancers (41), 
including prostate cancer (42, 43).  
While there is overwhelming evidence (2, 5, 17, 18, 44, 45) to demonstrate that 
ID4 is epigenetically silenced in prostate cancer, the underlying mechanism remain 
unexplored. In this study, we hypothesized that “ID4 is epigenetically silenced in prostate 
cancer due to association between histone modifications and DNA methylation.” To 
investigate this hypothesis, the following two aims were proposed:   
1. To demonstrate that ID4 is silenced due to promoter hypermathylation in prostate 
cancer. 





REVIEW OF LITERATURE 
 
2.1 Prostate development 
Prostate is a male reproductive organ that is located in front of rectum and just 
below bladder (Figure 1A). It aids in liquefying the seminal fluids. In most mammals 
prostate development begins during their second and third trimester of gestation period 
(46).  Prostate is derived from fetal urogenital sinus (UGS) during embryogenesis, which 
is surrounded between embryonic bladder and pelvic urethra (47). Prostate gland 
development is an androgen-dependent process (48).  Androgen receptor (AR) activation 
by binding of fetal circulating testosterone in UGS mesenchyme (UGM ) release signals 
that activate UGS epithelium to initiate cell proliferation from prostate ductal progenitors 
and regulate cell adhesion to permit prostate bud outgrowth (47, 49) or budding. Three 
distinct phases of prostate budding are specification, initiation and elongation. 
Specification phase determines where buds will form in the UGS, followed by initiation 
of prostatic bud formation in initiation phase. Cell adhesion, migration, proliferation and 
coordination of prostatic bud into UGM constitute the elongation phase (50, 51). 
 The prostate is located at the neck of the bladder in humans and dogs, while in 
rodents it is a combination of paired glandular organs above the bladder (1). To a large 




surrounds urethra and functions to contribute fluid to semen (53). Thus, mouse prostate is 
most convenient model system. In first 2 to 3 weeks after birth, mouse epithelial/stromal 
cellular differentiation and branching morphogenesis occurs (52). During branching 
morphogenesis, the once solid epithelial cord branch into a complex network of glands. 
Prostatic differentiation is complete by 5 weeks of age, resulting in adult mouse prostate; 
by 6 weeks, the mice are sexually active (54, 55). Mouse prostate is composed of 
multiple lobes: the dorsal, lateral, ventral and anterior. The dorsal and lateral lobes are 
surrounded and connected to urethra and sometimes examined as a single lobe which is 
referred to as the dorso-lateral prostate (54).   
In 1975, Tissel and Salander described anatomically four distinct lobes for human 
prostate: central zone, transition zone and peripheral zone (56, 57) (Figure 1B). The 
peripheral zone is the closest area of the prostate to rectum. It is the largest zone of the 
prostate gland and 75% of prostate cancers are observed in this zone (58). The transition 
zone is the central region of the prostate gland between peripheral and central zone (59). 
It surrounds urethra and is the smallest zone in normal prostate (occupies approximately 
20% of prostate gland) until age of 40. With increase in age, it enlarges and becomes the 
largest area of the prostate and pushes peripheral zone towards rectum, benign prostatic 
hyperplasia (BPH), a nonmalignant overgrowth (57, 60, 61). The central zone is located 
posterior to the transition zone and is surrounded by ejaculatory ducts (62) and is rarely 
associated with cancer (59).  Histologically, prostate mainly consists of three different 
cell types (Figure 2): Luminal epithelial cells, Basal cells and neuroendocrine cells. 




androgen–dependent and produce prostate secretions (65, 66). Androgen receptor and 
cytokeratins 8 and 18 are luminal epithelial cell markers (66). Basal cells are second most 
abundant cells and form a continuous layer between basement membrane and luminal 
epithelial cells (67). Basal cells are characterized by expression of p63 and Cytokeratins 4 
and 14 (63).  Neuro endocrine cells are third prostatic epithelial cells in normal prostate 
cells, which are androgen-independent and are present throughout basal layer. These cells 
are in minor population and are characterized by the expression of chromogranin A, 
serotonin and neuropeptides (68). Epithelial glands are surrounded by a thick layer of 
stroma, which mainly consists of smooth muscle. Smooth muscle alpha-actin and 
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Figure 1: Adult Prostate and Classification of Zones. A: The prostate gland is part of 
the male reproductive system. The prostate is located below the bladder. It surrounds the 
urethra. Image taken from http://www.fairview.org/healthlibrary/Article/. B: The three 
histologically distinct zones are shown: the central zone, the transitional zone, and the 
peripheral zone. Figure taken from Prostate Histology April 13, 2012 (2003-2012) 
Pathology Outlines.com, Inc. 
 
    
 
 
Figure 2: Different cell types in adult 

















2.2 Prostate cancer incidence and progression 
Prostate cancer is the most frequently diagnosed cancer and second leading cause 
of cancer related death among men in the western population, including United States 
(69). It is estimated that one out of every seven African Americans and one out of every 
eight Caucasians will be diagnosed with the disease. In 2013, 238,590 cases were 
diagnosed and 29,720 deaths were estimated (70). In 2014, it is estimated that 233,000 
new cases will be diagnosed with 29,480 estimated deaths. This constitutes to about 5% 
of all cancer deaths in western population (71). The high mortality rate in prostate cancer 
is due to late detection of disease. Studies have shown that 87% of men treated when 
diagnosed at early stage have 5 years of life expectancy (72).  
Most of the prostate cancers are adenocarcinomas, which arise from glandular 
epithelial cells. Prostate cancer rarely cancer begins from the tissues surrounding the 
gland (73). Prostate intraepithelial neoplasia (PIN) is defined by “neoplastic growth of 
epithelial cells within pre-existing benign prostatic acini or ducts” (74). PIN is widely 
accepted as precursor to prostate cancer (75). Prostate carcinoma is usually observed near 
the surface of the glands, which can be diagnosed during a digital rectal examination 
(72). As the tumors grows, the prostate expands around urethra and cause urinary 
problems with time it starts to invade surrounding organs such as seminal vesicle, neck of 
the bladder, lymph nodes and later prostate cancer can spread to bones, spine and hip 
pelvis. Metastasis often occurs to the lungs, liver and adrenal glands (76). 
American cancer society has identified five risk factors which may increase the 




and diet (77). It has been found that African Americans have higher rates of prostate 
cancer incidence compared to that of Caucasians and Asian men (78).  The risk of 
prostate cancer increases with age: one out of 6 American men during their life time is 
diagnosed with the disease (72). The therapeutic approaches such as radical 
prostatectomy and radiotherapy are considered curative for localized disease, yet no 
treatments for metastatic prostate cancer are available that significantly increases patient 
survival (79). Epidemiological studies have shown that environmental factor, such as diet 
is also a factor that increases the risk of prostate cancer. 
2.3 Known mechanisms in prostate cancer   
Over the past several years significant efforts have been invested in understanding 
the molecular basis of prostate cancer.  A number of mouse models (Pten-/- (80), Myc hi/ 
lo (81), Nkx3.1-/- (65), Id4-/- (16) and reviewed in (82)) have been developed that 
recapitulate several aspects of human disease initiation and progression. Most, if not all, 
of the studies have pointed towards the central role of androgen receptor (AR) in prostate 
cancer (83, 84).  AR, a member of the nuclear receptor superfamily, is required for 
normal prostate function and is involved in cyto-differentiation of the prostate epithelial 
cells (85).    In a majority of prostate cancer cases, AR function contributes to the 
survival and proliferation of cancer cells in primary disease and in most cases the 
presence of AR continues to be indispensable after progression to hormone independent 
disease (48, 86).  However, the prostate epithelial specific AR knockout mouse (87, 88) 
also develops prostate cancer, suggesting that AR function is not absolutely required for 




where a familial mutation in a single gene leads to a higher risk of developing the 
respective cancers, no such major risk allele has been identified for prostate cancer to 
date. The heterogeneity of prostate cancer (89) suggests that there could be multiple 
initiating events leading to inactivation of tumor suppressors and/or activation of tumor 
promoters/ oncogenes that could at some point of disease progression cross-talk with AR 
(89).  These early or late events may promote the transition of androgen receptor from a 
tumor suppressor to an oncogene.  
2.4 ID proteins 
The inhibitor of DNA-binding (ID) proteins, ID1-4 are negative regulators of 
basic Helix-Loop-Helix (bHLH) transcription factors. The basic helix-loop-helix (bHLH) 
transcription factors regulate tissue-specific transcription and regulate many 
developmental pathways (90). ID proteins lack the basic domain and can form 
transcriptionally inactive heterodimers with bHLH proteins. In doing so, ID proteins can 
alter the transcription of genes that are dependent on the functional dimerization between 
bHLHL proteins (91-93) (Figure 3).  The interaction repertoire of ID proteins also 
involves several non-bHLH proteins, whereas all ID proteins interact with bHLH TCF3, 
their interaction with non-bHLH proteins appears in large part to be isoform dependent - 
ID1: CASK, ELK1, GATA4, caveolin; ID2: ELK1, 3 and 4, CDK2, PAX2, 5 and 8, Rb 
and related pocket proteins, ID3: ELK1 and 4, ADD1 ((9, 94) and public database). 
Specific non-bHLH interaction partners for ID4 are currently not known. Thus, ID 
proteins are capable of regulating the expression of a large number of genes through 
 
specific bHLH and non-bHLH interactions that in turn regulates many
such as cell growth, differentiation, and apoptosis 
 
Figure 3:  ID sequence and protein structure comparison.
conserved HLH domain sequence (box). ID4 has poly
and poly-Proline (from amino acid 118 to 124) outside of HLH domain, which may allow 






 cellular processes 
(94-101). 
  ID proteins shared a 








ID proteins are expressed in different tissues and show distinct expression 
patterns at different stages of development in a region specific manner (102-104). During 
embryogenesis, ID1, ID2 and ID3 expressions are overlapping, whereas ID4 shows a 
unique expression pattern (103). In mouse embryogenesis, ID1, ID2 and ID3 are 
expressed in multiple tissues which undergo active morphogenic activities, but ID4 is 
mainly detected in neural tissues and in ventral portion of the epithelium of the 
developing stomach (10).  ID proteins are expressed by essentially all cell lineages at 
some point of development. In general, ID expression is highest in undifferentiated, 
proliferating populations and is down-regulated as cells exit the cell cycle and terminally 
differentiate (reviewed in (8, 9, 94)).  Tissues such as salivary gland, kidney and lung, 
which undergo epithelial-mesenchymal interaction, also express ID proteins (102, 104). 
Knock out mouse models evaluating ID genes have demonstrated their essential 
role in development. Id2 null mice display phenotypic abnormalities of retarded growth 
and neonatal morbidity due to a lactation defect (105), impaired chondrogenesis (106), B 
cell development (107) and severe cardiac defects (108).  Male Id2-/- mice exhibit 
defects in spermatogenesis (109). Id3 null mice develop primary Sjögren’s syndrome-like 
symptoms (110), specific defects in B/T lymphocyte development (111), and restricted 
development of the gamma delta lineage during thymopoiesis (112). Interestingly, no 
phenotype is observed in mice lacking only Id1 suggesting that its function can be 
effectively compensated by the other three Ids.  So far embryonic lethality has been 
observed only in mice homozygously lacking both Id1 and Id3 suggesting that Id1 and 




In general, the expression of ID proteins (ID1-ID3) is high in proliferating cells as 
they promote cell proliferation (7, 8) and then expression is down regulated during 
differentiation (9). As key regulators of cell cycle and differentiation, the expression of 
ID proteins is increasingly observed in many cancers and in most cases associated with 
aggressiveness of the disease including poor prognosis (113-116), metastasis (117) and 
angiogenesis (11, 118).  Of all the four ID proteins, the expression of ID1, ID2 and to a 
lesser extent ID3 in cancer and the underlying molecular mechanism is relatively well 
known.  On the contrary, the underlying mechanism in epigenetic silencing of ID4 in 
many cancers is unexplored (2).  
2.5 ID4 
2.5.1. ID4 in development 
ID4 expression is both conflicting and atypical compared to other members of ID 
family during development (2, 119). Unlike other ID proteins, ID4 is highly expressed 
during premature differentiation of early cortical stem cells (120-122). ID4 also plays 
important roles in development of different organs such as neural compartments and 
mammary gland. In the mammary gland, ID4 is expressed in subset of luminal epithelial 
and basal cells (123, 124). ID4 is required for normal brain size and lateral expansion of 
the proliferative zone in the developing cortex and hippocampus possibly by regulating 
neural stem cell proliferation and differentiation (125). Targeted deletion of Id4 in mouse 
memory gland leads to a delay in ductal morphogenesis as well as cell proliferation and 




ablated mammary gland results in reduced proliferation and increased apoptosis. Thus, 
ID4 promotes mammary gland development by suppressing p38MPK activity (124). 
  In neural progenitor cells, ID4 inhibits oligodendrocyte differentiation by 
directly binding to OLIG1 and OLIG2 (126), key bHLH proteins involved in 
oligodendrocyte differentiation (126-128). ID4 promotes astrocytic differentiation by 
mediating inhibitory effects of bone morphogenic protein (BMP) (122, 127). During 
development, oligodendrocyte production is hampered in Id4 knockout mice causing 
embryos not to differentiate, suggesting important role of ID4 in oligodendrocyte 
development (129). Examination of the ovaries of Id4 knockout mice shows significantly 
increased number of secondary and antral follicles and considerably low uterine weight 
(130). In prostate, Id4 knockout attenuates prostate development with fewer tubules, 
smaller tubule diameter and subtle mPIN like lesions due to progressive loss of 
undifferentiated spermatogonial stem cell population during adulthood (131). This study 
shows the role of ID4 in regulation of self-renewal of mammalian germ line stem cell 
population. Additionally, ID4 plays an essential role in G1-S phase transition and 
knockdown of ID4 results in inhibition of progression into S-phase (125). 
2.5.2 ID4 as tumor promoter versus tumor suppressor 
Paradoxically, ID4 appears to demonstrate both pro-tumor and anti-tumor 
properties. Epigenetic silencing of ID4 in leukemia (19), breast (132, 133), colorectal 
(134) mouse and human CLL (chronic lymphocytic leukemia (25)) and gastric cancer 
(29) tend to support its anti-tumor activity. Whereas high ID4 expression in a B-cell acute 




ALL) (136) due to t(6;14)(p22;q32) chromosomal translocation and in bladder (137) and 
rat mammary gland carcinomas (138) suggests that it may have pro-tumor activity also 
(Table 1). 
2.5.3 ID4 as a tumor suppressor 
Epigenetic silencing of tumor suppressor genes due to promoter hyper-
methylation has become a common mechanism in cancer. ID4 promoter contains two 
CpG islands in its promoter which makes it susceptible for DNA methyltransferase 
(DNMTs) dependent hyper-methylation. Epigenetic silencing of ID4 due to promoter 
hyper-methylation has been observed in many cancers (132, 139) (25, 29, 134, 140) as 
discussed above. 
Study conducted by Noetzel et al. demonstrated that in 68.9% of primary breast 
cancer samples ID4 expression is reduced due to promoter hyper-methylation. They also 
observed that decrease in ID4 expression is associated with unfavorable recurrence-free 
survival and also increases patient’s risk for lymph node metastasis (139). Based on data 
mining of published microarray databases in Oncomine database (Figure 4), it is 
observed that ID4 is highly expressed in the normal, normal adjacent and benign 
prostates and its expression is significantly decreased in prostate cancer (2). These 
observations are however, contradictory to an earlier study that demonstrated increased 
expression of ID4 in prostate cancer, but negligible expression in the normal prostate 
(141). Earlier studies also suggested that ID4 is regulated by androgens in normal 
prostate epithelial cells (44) and in androgen sensitive prostate cancer cell line LNCaP 
(5). ID4 expression is low in PC3 prostate cancer cells, but undetectable or weakly 
 
expressed in DU145 prostate cancer cells due to promoter 
Ectopic ID4 expression also attenuates cell proliferation i
with increased expression of cyclin dependent kinase inhibitors p21and p27 




Figure 4: ID4 expression in Prostate 
data from four independent studies, ID4 is significantly down regulated in prostate cancer 
compared to normal. Abbreviations: n: Number of samples in each analysis, PC: Prostate 
Cancer (Red), MPC: Metastatic pro
hyper-methylation
n DU145 cells that is associated 
2, 5, 44) demonstrate that ID4 acts as a potential tumor 
cancer from Oncomine database.
state cancer (Yellow), NAP: Normal adjacent prostate 
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(Blue). NP: Normal prostate (Blue), PP: Post-pubertal prostate (Blue), BP: Benign 
prostatic hyperplasia (Blue), PIN: prostate intra-epithelial neoplasia (green). 
 
2.5.4 ID4 as a tumor promoter 
It is known that genes that are involved in development also promote cancer 
progression (142). Therefore, in some cases such as breast, ovarian, glioblastoma, and 
bladder cancer it is observed that overexpression of ID4 promotes tumor progression. In 
glioblastoma, enforced ID4 expression results in increased Cyclin E and Jagged 1 
expression, resulting in malignant transformation of astrocytes by converting them into 
neural stem-like cells (143). ID4 also down regulates BRCA1 in breast and ovarian 
cancers (144, 145). In ovarian cancer, Ren et al. found that by delivering tumor-
penetrating nanocomplex containing small inferring RNA against ID4 into mice bearing 
ovarian cancer resulted in tumor suppression and increased survival suggesting that ID4 
acts as an oncogene in high- grade ovarian cancers (146). ID4 acts as a tumor promoter in 
a small set of bladder cancer. In advanced bladder cancer over expression of ID4 
appeared due to gene amplification (137). High ID4 expression has been reported in B-
cell acute lymphoblastic leukemia (135) and B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL) (136) due to the t(6;14)(p22;q32) chromosomal translocation 
(137). 
2.5.5 Transcriptional regulation of ID4  
The molecular mechanism by which ID4 expression is regulated has not been 




proximal promoter is rich in CpG islands (CGI) (29). The CGI rich promoters also tend to 
be enriched for Sp1 and E-Box response elements. In fact, Sp1 and E-box transcription 
factors within the CGIs around the TATA box are also required for ID4 transcriptional 
regulation (147). Therefore, accessibility of CG rich regulatory sites such as Sp1 and E-
Box within CGIs are dependent on CpG methylation. Indeed, in many of the cancers 
listed above including prostate, ID4 promoter is hypermethylated around the TATA box. 
Recent studies conducted by Huang et al. in oligodendrocyte differentiation found that 
protein arginine methyltransferases (PRMT5) regulated ID4 expression (148). PRMT5 is 
a type II protein arginine methyltransferase that catalyze monomethylation and 
symmetric dimethylation of arginine residues (149, 150). siRNA mediated silencing of 
PRMT5 in mouse primary oligodendrocyte progenitor cells resulted in high expression of 
ID4 and abrogated oligodendrocyte differentiation (148). Moreover, a detailed molecular 
mechanism reveals that PRMT5 positively regulates DNA methylation by recruiting 
DNMT3a within the CpG islands of ID4 promoter (148). Thus, ID4 gene methylation is 
regulated by PRMT5 in glial cells results in silencing of ID4.  
2.5.6 ID4 in prostate cancer 
ID4 is required for normal prostate morphogenesis where it is specifically 
expressed in the luminal epithelial cells (16). Loss of ID4 expression is frequently 
observed in prostate cancer suggesting its essential role as a tumor suppressor (4, 17). In 
prostate cancer, ID4 expression is progressively lost with increasing stage of the disease 
(4). In 2009, Carey et al. have shown that treatment of DU145 cells with global 




gene and protein expression (2). Thus, loss of ID4 in prostate cancer is primarily due to 
promoter hyper-methylation (2, 4, 17). Knockdown of ID4 in LNCaP prostate cancer cell 
lines results in aggressive growth, increased cell survival and acquisition of castration 
resistance phenotype usually associated with advanced disease (18). Previous studies 
demonstrated that knock down of Id4 in mice affects normal spermatogenesis and 
develop prostatic intra-epithelial neoplastic lesions (PIN) as early as six weeks (48). 
These results suggested that loss of ID4 expression could be an early event in prostate 
cancer (16). 
2.5.7 ID4 and AR 
Androgen receptor (AR) acts as a tumor-suppressor in the normal prostate, but 
transitions to an oncogene in prostate cancer (PCa) that eventually leads to castration 
resistant prostate cancer (CRPC) (151). AR activation in response to circulating 
androgens in the early stages of the disease and later to intra-tumoral androgens as a 
result of de novo steroidogenesis appears to be a key transitional event (152). AR 
expression and cellular localization within Id4-/- and wild type prostate is similar, but AR 
transcriptional activity in Id4-/- mice is attenuated resulting in decreased expression of 
Nkx3-1, an androgen regulated gene required for normal prostate development (16).  ID4 
is highly expressed in the androgen sensitive prostate cancer cell line LNCaP which has 
low tumorigenic potential (2, 4). On the contrary, ID4 is epigenetically silenced in highly 
tumorigenic C81 prostate cancer cell line (4).  C81 cells are AR positive, but androgen 
insensitive derivatives of LNCaP cells cultured progressively in androgen deprived 




tumor suppressor possibly by regulating normal AR activity in the prostate. Id4 also 
restores androgen receptor expression and activity in the androgen receptor negative 
prostate cancer cell line DU145 (2). These results suggest that Id4 could potentially act 
within the androgen receptor pathway to regulate the development and function of the 
prostate. 
2.5.8 ID4 and p53 
In 2013, Knowell at al. observed that ectopic expression of ID4 in prostate cancer 
cell line DU145 leads to an increase in expression levels of p53 target proteins BAX, 
PUMA and p21, further resulting in increased apoptosis. Gain of ID4 results in increased 
acetylation of p53 by promoting the assembly of CBP/P300 complex. Thus, suggesting 
that ID4 regulates the activity of wild type and mutant p53 (154).  
Fontemaggi and colleagues have extensively characterized the molecular 
interaction between ID4 and mutant p53 in promoting neo-angiogenesis in breast cancer 
(155). In this study, they found that gain of function mutant of p53 together with 
transcription factor p65 and E2F1 assemble at the region of ID4 promoter and 
transcriptionally enhances its expression (155). In this way ID4 stabilizes certain pro-
angiogenic factors, which assembles mutant p53 functions and induce angiogenesis 
(155). But how ID4 regulates the activity of p53 is not clear. It has been shown that ID4 
regulates neural stem cell proliferation and differentiation (129).  
2.6 Epigenetics  
The definition of epigenetics has evolved over a period of time since the term was 




products, which bring the phenotype into being” (156). In broadest terms, epigenetics is a 
bridge between genotype and phenotype, a phenomenon that changes the final outcome 
of a locus or chromosome without changing the underlying DNA sequence (156) (Figure 
5). Chromatin modifications, both covalent and non-covalent are currently considered as 
hallmarks of changes in epigenetic landscape (157). Both DNA and histones, the two 
basic components of the chromatin undergo these modifications to influence on 
chromatin structure and gene expression. Depending upon the type and location, these 
modifications alter multiple cellular processes such as gene regulation (158), cellular 
differentiation (159), stem cell development (160) and DNA replication (161, 162). 
  
 
   
Figure 5: Epigenetics Mechanisms:
regulations are DNA methylation and histone modifications 
2.6.1 Cancer as an Epigenetic disease
Multiple genetic changes must occur to promote the cancer phenotype 
According to the classical mechanism, genomic instability (deletions or translocations) 
due to inactivating mutations in tumor suppressor genes or gain of functio
oncogenes resulting in uncontrolled growth is considered as a tumor initiating event. 
More recently, loss of function (expression) through epigenetic changes due to altered 
pattern of DNA methylation and histone modification, is gaining sign
 
 The two main mechanisms involved in epigenetic 
(290). 
 








an additional pathway involved in cancer initiation and progression (164-166). Thus, 
combined genetic and epigenetic changes are now considered as cancer initiating events. 
As discussed above, aging, environment, and inheritance (familial) are the three major 
risk factors in prostate cancer. All three of these risk factors are intricately linked to 
epigenetic alterations in genomes that can lead to global changes in gene expression 
patterns which are generally pro-tumor. Several epigenetic alterations, such as global 
hypomethylation and CpG island hyper-methylation, are progressively accumulated 
during aging and directly contribute to cell transformation (167). 
Recent advances suggest that epigenetic mechanisms mediate the effect of 
environmental factors on the genome by disrupting cellular processes which contribute to 
higher cancer risk (168). More recently, the concept of generational threshold in prostate 
cancer incidence is also gaining attention. Prostate cancer risk is usually low in recently 
migrated populations, but within three generations, the risk of prostate cancer among 
these migrant populations is almost similar or higher to the native host country 
population. This generational threshold appears, in part, due to epigenetic alterations and 
not due to mutations in the F0/F1 generations (parental/offspring adopting a more 
westernized lifestyle). These epigenetic changes could predispose the inherited genome 
of subsequent generations to mutagenic/genotoxic alterations leading to the development 
of sporadic prostate cancer (169). Differences in epigenetic changes are also observed 
that associate with high risk of prostate cancer in African American men. Specifically, 
increased methylation is observed for NKX2-5 and TIMP3 in the normal prostate from 




carcinogenesis. Large set of genes are epigenetically regulated in prostate cancer (Table 
2). 
Table 2. List of genes that are epigenetically silenced in prostate cancer: (2) (3) (4) (5) 
(6) (7) (8) (9) 
 
Target Function Epigenetic 
modification 
DAB 2 interacting protein 
(DAB2IP) 
Inhibition of NF-κB/Ras 
pathway 
Histone methylation 
Adrenoceptor Beta 2 
(ADRB2) 
Β-adrenergic signaling Histone methylation 
E-Cadherin (CDH1) Cell-cell adhesion, 
Tumor suppressor 
Histone methylation 
prostate secretory protein 
of 94 amino acids (PSP94) 
Inhibits MMP secretion Histone methylation 
Slit homolog 2 (SLIT2) Chemorepellent protein Histone methylation 
TIMP metallopeptidase 
inhibitor 2/3 (TIMP2/3) 
ECM degradation Histone methylation 
Raf-1 kinase inhibitor 
protein (RKIP) 




Kruppel-like factor 2 (KLF 
2) 
Tumor suppressor Histone modification 
Prostate Cancer Associated 










coli (APC),  
Retinoic Acid Receptor 
beta (RARβ),  
RAAF1,  Inhibitor od DNA  




Androgen Receptor (AR), 
Estrogen Receptor 1 
(ESR1),  
Estrogen Receptor 2 
(ESR2) 
Hormone receptor genes DNA methylation 




Cyclin D2 (CCND2), 
CDKN1B, 
 Stratifin (SFN) 
Cell- cycle control genes DNA methylation 
Growth arrest and DNA-
damage-inducible protein 
GADD45 alpha 
(GADD45a), PYD And 
CARD Domain (PYCARD) 
, RPRM, GLIPR1 










2.6.2 DNA methylation 
DNA methylation includes the addition of a methyl group to cytosine residues of 
CpG dinucleotides (171). DNA methylation is a well-studied and first epigenetic 
modification to be observed in cancer cells. Hyper-methylation of CpG islands on tumor 
suppressor gene leads to silencing of the gene, whereas global hypomethylation leads to 
genome instability and overexpression of tumor promoter genes (172).  DNA methylation 
in mammals is established by two DNA methyltransferase enzymes; DNMT1 and 
DNMT3 family (Figure 6). DNMT1 the first methyltraferse to be discovered (173), is 
involved in copying methylation patterns after DNA replication, so it is referred to as 
“maintenance” methylatransferase (174). DNMT1 knock out revealed that DNMT1 plays 
an important role in proper embryonic development, imprinting and X-inactivation (174-
176). Recently, inactivation of DNMT1 in colon adenocarcinoma cell line revealed that 
there were no profound growth abnormalities and retained 80% methylation levels, which 






Figure 6: DNA Methylation:
5’cytosine. It is established, maintained and catalyzed
DNMT3a and DNMT3b. DNMT3a and DNMT3b are involved in de nova methylation 
and DNMT1 is involved in maintenance. 







 DNA methylation is addition of methyl group to 









DNMT3 family was discovered in 1998 by Okano et al. characterized DNMT3 
family into DNMT3a and DNMT3b (177). At the amino acid levels the human and 
mouse DNMT3 enzymes are highly conserved (approximately 95%) (178). DNMT3 
family is not only involved in de nova methylation of CpG islands (179), they are also 
involved in methylation of non-CpG islands such as CpA or CpT in embryonic cells 
(180).  Knock out mice studies have revealed that DNMT3a knock out mice die at about 
4 weeks of age, but DNMT3b knock out mice are not viable and showed numerous 
developmental defects and growth impairments (179). DNMT3b is also involved in 
maintenance of DNA methylation of minor satellite repeats adjacent to centromeres of 
chromosomes 1, 9 and 16 resulting in instability of these chromosomes. It is observed 
that mutations in catalytic domain of DNMT3b results in loss of DNA methylation from 
satellite 2 and 3 sequences adjacent to the centromeres in patients with 
immunodeficiency, centromeric in-stability, facial abnormalities (ICF) syndrome (179, 
181, 182).   
Knock out mice experiments showed that homozygous deletion of DNMT3a and 
3b in embryonic stem cells did not alter pre-existing methylation, whereas homozygous 
deletion of DNMT1 resulted in approximately 70% reduction in methylation supporting 
role of DNMT1 in methylation. In contrast, enforced overexpression of DNMT1 in 
cancer cell lines resulted in de nova methylation of CpG Island, indicating that DNMT1 
is also involved in de nova methylation (183). Rhee et al. showed that somatic cells 
lacking DNMT1 retained 80% of their methylation without alteration in DNMT3a and 3b 




methyltransferases that can compensate for DNMT1. It is also possible that all three 
DNMTs possess both de nova and maintenance functions and methylates certain genomic 
regions by interacting with other nuclear proteins or DNA binding factors. De-novo DNA 
methylation of certain gene promoter associated CpG di nucleotides occurs rarely in 
normal prostate epithelial cells, but its frequency increases in prostate cancer. This 
phenomenon is, in part, thought to be supported by an increase in the expression of 
DNMT1 in prostate cancer cells when compared to their normal counterparts (185). Thus, 
DNA methylation in the promoter region of tumor suppressor genes is likely an important 
epigenetic mechanism involved prostate cancer initiation and progression (186). 
2.6.3 Histone Modifications 
Histones are no longer considered as simple “ DNA packaging” molecules as they 
are  involved in the dynamic regulation of a large set of genes through reversible post 
translational modifications that occur on their N-terminal tails, which are rich in 
positively charged amino acids (187). The histone post-translational modifications 
include acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ADP 
ribosylation, deimination and proline isomerization (188, 189). Among these 
modifications, acetylation and methylation are well studied in prostate cancer.   
2.6.4 Histone acetylation 
Evidence indicates that the accumulation of acetylation and methylation at 
specific histone lysine or arginine residues plays a prominent role in gene regulation 
(189, 190). In general, histone acetylation is associated with gene activation and histone 




transferases (HAT) such as PCAF, CBP/P300 are altered in many cancers; on the other 
hand alterations in HADCs are less common. For instance, p300 a HAT gene is mutated 
in gastrointestinal tumors (193) resulting in truncated protein or often associated with 
amino acid substitution at conserved residues in critical domains on p300 protein (194). 
Histone acetylation and de-acetylation catalyzed by a group of enzymes collectively 
termed as histone acetyltransferases (HAT) and histone de-acetylases (HDAC) 
respectively, have emerged as the central mechanism in regulating various events leading 
to prostate cancer (195).  Multiple proteins with HAT and HDAC (HDAC1-11) activities 
are also known to target non-histone proteins (196).  As would be expected, certain 
HDACs are increased in prostate cancer (HDAC1, HDAC2 and HDAC3) (Reviewed in 
(197)). Paradoxically, the expression of HAT p300 is also increased in prostate cancer. In 
prostate cancer, HATs such as p300/ CBP may target non-histone proteins such as AR.  
Acetylation of AR is a gain of function modification that promotes prostate cancer cell 
growth (198). 
2.6.5 Histone methylation 
Methylation plays dual role by regulating histone accessibility both as activation 
and silencing of transcription (199). Methylation is a complex process; it occurs at lysine 
or arginine residues and can be mono, di- or tri- methylation.  Methylation of arginine is 
linked to activation of genes and methylation of lysine is linked to gene silencing, 
heterochromatin formation and X-inactivation and genome imprinting (200). Histone 
methylation appears to play a more complex role in gene regulation (201). Arginine is a 




methylation promotes gene transcription is unknown (199).  Methylation on arginine can 
be mono methylated, symmetrically di-methylated or asymmetrically di-methylated, 
whereas lysine residues can accept up to 3 methylations. In mammals, so far there are 5 
argenine residues (H3R2, H3R8, H3R17, H3R26, and H3R3) and 6 lysine residues 
(H3K4, H3K9, H3K27, H3K36, H3K79 ) on histone 3 and histone 4 (202). Generally, 
methylation on lysine residue results in gene silencing, but it can also contribute to gene 
activation. One, two or three methyl groups can be added to lysine residue by histone 
methyl transferases (HMTs) (200). These HMTs catalyze the transfer of a methyl group 
from S-adenosyl-L-methionine (SAM), a methyl donor to the –NH2 group of lysine 
residue (190). All lysine methyltransferases except Dot1/Dot1L contains an evolutionary 
conserved SET domain (203).  Large number of SET domain containing HMTs are 
associated with cancer (204). Knock down of these enzymes are very susceptible to 
cancer, especially B cell lymphomas (172). Methylation of H3K4 and to a lesser extent 
H3K48 and H3K79 are associated with gene activation, whereas methylation at H3K9 
and H3K27 are associated with gene silencing (205).  Some promoters simultaneously 
carry both gene activating H3K4Me3 and inactivating H3K27Me3 marks and are known 
as bivalent promoters (206).  Such bivalent marks could be required for the maintenance 
of embryonic stem cell gene expression patterns (206).  Identification of such 
modification in cancer stem cells is proposed, but remains to be investigated (207). In 
prostate cancer, increasing evidence suggests that large numbers of histone modifications 
are associated with changes in histone-modifying enzymes such as histone 




2.6.6 Polycomb group proteins 
From Drosophila to mammals, many pathways such as polycomb group and 
trithorax (TrxG) group proteins are highly conserved to maintain the cell identity and 
transcriptional patterns which are established in the first stage of embryonic life and 
adulthood (208). PcG and TrxG group proteins consists of multi-protein complex proteins 
which can regulate repressed and active genes involved in development and cell cycle 
regulation. These groups are involved in chromatin modification and change its structure 
(37, 209). They perform their epigenetic functions by binding to their specialized DNA 
elements, Polycomb/trithorax Response elements (PREs/TREs) (210, 211). Initially, 
TrxG and PcG were identified in Drosophila by genetic screening to establish and 
maintain homeobox (Hox) gene expression patterns, but recent studies have shown the 
proteins bind to thousands of chromosomal sites along with Hox genes (210).  
Polycomb group (PcG) proteins are important epigenetic regulators of genes 
involved in differentiation, cell proliferation and stem cell renewal through histone 
modifications (42). In Drosophila, human and mouse embryonic stem cells, PcG proteins 
repress developmental transcription factors that promote differentiation to maintain stem 
cell plasticity and pluripotency (212, 213). From recent studies it is observed that certain 
sequence specific DNA binding proteins such as Yin Yang 1 (YY1) are capable of 
recruiting PcG complexes, but its initial recruitment to silence specific target gene is not 
yet clear. However, along with YY1 binding sites they need association of other 
chromatin modifiers such as HDACs for proper functioning of PcG complex proteins 
 
(214). PcG proteins appear
Polycomb-repressive complexes (PRCs) (Figure 7). 
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Figure 7:  Polycomb repressive complex: 
complexes. A Polycomb repressive complex consists of PRC1, PRC2, PRC3 and PRC4. 
These are active in progenitor cells and tumor cells that have stem
(291). B: Binding of PRC2 complex on PCG target gene
such as ubiquitylation of H2AK119, Chromatin compaction, recruitment of DNMTs to 
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2.6.7 Polycomb repressive complex 1 (PRC1) 
A heterogeneous polycomb-repressive complex 1 (PRC1), is formed by Ring 
finger protein 1 and 2 (RING1 and RING2), B lymphoma Mo-MLV insertion region-1 
homolog (BMI1), Polycomb group ring finger 2 (MEL18), PH, Polycomb group ring 
finger 1 (9NSPC1), Mel18 and Bmi1-like Ring finger (MBLR) and Chromobox homolog 
(CBX) proteins. PRC1 complex is involved in many functions such as maintaining gene 
silencing, preventing transcriptional elongation of RNA pol II (215) and histone 2A 
(H2A) lysine 119 (K119) ubiquitylation (Figure 7). PRC1 is recruited by H3K27Me3, 
PRC2 epigenetic mark to maintain gene repression. Chromodomain of polycomb (Pc) in 
PRC1 recognizes this epigenetic mark (H3K27Me3).  
2.6.8 Polycomb repressive complex 2 (PRC2) 
The second complex of PcG proteins is polycomb repressive complex 2 (PRC2), 
which is Enhancer of zesta homolog 2 (EZH2), Suppressor of zeste 12 (SUZ12) and 
Embryonic Ectoderm Development (EED) proteins. PRC2 complex is involved in the 
initiation of gene silencing through histone methylation (216). The mechanisms by which 
PRC2 targets specific chromatin is unclear, but noncoding RNAs (ncRNAs) such as Xist 
(X inactive specific transcript) and HOTAIR (HOX antisense intergenic RNA) have been 
shown to interact with PRC2 and facilitate its recruitment (217). In 2002, Kuzmichev et 
al. identified that PRC2 complex exhibits histone methyl transferases (HMTase) activity 
and could specifically methylate H3K9 and H3K27 (140, 213). This complex is strongly 
involved in the early steps of embryogenesis. PRC2 is the first complex to be recruited on 




maintain the gene silencing by preventing RNA Pol II biding to DNA, and recruiting 
HDACs (215, 218). The PcG proteins also regulate genes involved in signaling pathways 
like WNT, Transforming growth factor β (TGFβ) , and Bone morphogenetic protein 
(BMP) (218, 219). EZH2 and EED knock out mice display embryonic lethality soon after 
implantation (215). As mentioned above, PRC2 complex is involved in regulation of 
developmental genes, and embryonic stem cells lacking PRC2 complex proteins are 
unable to differentiate and show aberrant de-repression of lineage-specific genes (220, 
221). 
 Some studies also reported polycomb repressive complex 3 (PRC3) and 
polycomb repressive complex 4 (PRC4) in cells (216). In humans, alterations in 
translation initiation sites resulted in four different EED isoforms. All these isoforms can 
interact with EZH2 resulting in the formation of different polycomb complexes. EED1 
and EZH2 form PRC2 complex and methylates H3K27 in the presence of histone 1 (H1). 
The two shortest isoforms, EED3 and EED4, with EZH2 can form PRC3 and methylates 
H3K27 in the absence of histone 1. EED2 along with SirT1 and EZH2 can form PRC4 
and methylates H1BK26 (222, 223). 
2.6.9 Enhancer of zesta homolog 2 (EZH2) 
In mammals, EZH2 gene is present on chromosome 7q35. It consists of 20 exons, 
encoding 746 amino acid residues. EZH2 is a member of PRC2 complex with 4 highly 
conserved domains: H1 and H II, cysteine rich domain and a SET domain at C-terminal. 
H1 and HII domains at N-terminal interact with other proteins such as EED, SUZ12 and 




and preferentially tri-methylates lysine 27 on histone 3 (225, 226). In embryonic stem 
cells, PcG proteins maintain pluripotency by repressing early differentiation genes. EZH2 
is also highly expressed in epidermal progenitor cells, but its expression decreases with 
terminal differentiation (227). EZH2 maintains the multipotent nature of stem cells. In 
hematopoietic stem cells (HSCs), overexpression of EZH2 leads to preserving long term 
repopulating potential (228). EZH2 is highly expressed in neural stem cells (NSCs) and 
its expression decreases after differentiation into astrocytes (229). In 2011, Sher et al. 
have shown that overexpression of EZH2 in astrocytes induces de-differentiation of 
astrocytes to NSCs. However, these EZH2 induced NSCs lack differentiation potential, 
indicating that overexpression of EZH2 alone is not sufficient for complete 
differentiation (230). 
 In normal cells, EZH2 expression is regulated by pRB-E2F pathway. In cell 
cycle, EZH2 levels are accumulated at early S phase so that H3K27Me3 marks are 
transmitted to newly synthesized chromatin. It is involved in epigenetic silencing of large 
number of genes involved in differentiation, proliferation and embryonic development 
(218). EZH2 is the only HMTase protein which tri-methylates histone 3 at lysine 27 to 
represses gene activity and it is used as a marker of EZH2 enzyme activity (212, 231). It 
is observed that PRC1 recognizes PRC2 methyl mark (H3K27Me3) and is recruited to 
the target promoters. Thus, EZH2 is a transcriptional repressor that plays a vital role in 
maintaining the homeostatic balance between gene repression and expression (226, 232).   




Over expression of EZH2 is found in prostate cancer (42, 233, 234), breast cancer 
(234-236) and melanoma (233). In breast and prostate cancer, EZH2 overexpression is 
associated with increase in neoplastic transformation (235, 237) and poor prognosis (42). 
In 2003, Bracken et al. identified that E2F1-3 regulates EZH2 expression levels. They 
observed that overexpression of pRB and p16, which represses E2Fs, results in decreased 
expression of EZH2, SUZ12 and EED in many cancers. It is observed that in vivo 
disruption of Rb-E2F-EZH2 signaling leads to bladder cancer (238).  In pRB knockout 
mouse embryonic fibroblasts, EZH2 and EED expressions are elevated. Furthermore, loss 
of p16 results in overexpression of EZH2, SUZ12 and EED both at mRNA and protein 
levels leading hyper methylation of PRC2 target gene (239). It is reported that EZH2 is 
down regulated in senescence cells due to down regulation of E2Fs by p21/waf1 pathway 
(240). In 2010, Cao P et al. observed that micro RNA 101 negatively regulated EZH2 and 
decreases the invasiveness of prostate cancer (241). In 2014, Liu et al. identified that 
microRNA-98 can inhibit EZH2 expression and cell proliferation by regulating pRB-E2F 
pathway in ovarian cancer stem cells (OSCS) (242).  
2.6.11 EZH2 and prostate cancer 
EZH2 plays an important role in proliferation both in transformed and non-
transformed human cells (243). Therefore, a decrease in EZH2 expression not only leads 
to proliferation disadvantage, but also results in cell cycle arrest in G2/M phase (42). 
Conversely, primary cells with ectopically expressed EZH2 proliferate faster (243), 
supporting EZH2 as oncogene. In prostate cancer and breast cancer EZH2 over 




clinical outcome (42, 235). In addition, increase in EZH2 expression is also observed in 
several other cancers such as gastric, lung, bladder and endometrial cancer (244). In 
prostate cancer EZH2 is involved in epigenetic silencing of many tumor suppressor genes 
such as DAB2 interacting protein (DAB2IP) (245), Adrenoceptor Beta 2 (ADRB2) (246), 
E-Cadherin (CDH1) (247) and KLF2 (248) (249) (Table 2). In nasopharyngeal carcinoma 
(NPC), EZH2 inhibits E-cadherin by forming a co-repressor complex with snail and 
HDAC1/HDAC2 resulting in aggressive and poor prognostic phenotype (250). These 
observations suggest an important role of EZH2 in cancer progression. Recent studies 
have shown that EZH2 is a potential therapeutic target (251). Histone methyltransferase 
inhibitors such as 3-Deazaneplanocin A (DZNep), GSK126 and GSK343 are being used 
as a therapeutic strategy for cancer. 
2.6.12 Association between Histone modifications and DNA methylation 
Histone modifications and DNA methylation can occur independently of each 
other; however, initial histone modifications can lead to altered DNA methylation.   
Significant crosstalk exists between the histone modifying and DNA methylating 
machinery (252, 253). An example includes the interactions between EZH2, the SET 
domain methyltransferase, part of the polycomb repressive complex 2 (PRC2), and DNA 
methyltransferases (224, 254). For instance, it has been observed that MYT1, a gene 
which is regulated by EZH2, is also regulated by DNMTs (40). Almost 47% of the genes 
regulated by DNMT3b are also bound by the PRC1/PRC2 complexes in colon cancer 
(255). However, there are other studies that show that EZH2 occupancy at a given locus 




showed that CDH1 and KLF2, both known to be regulated by EZH2 in prostate cancer, 
have no alterations of DNA methylation status on their promoters upon EZH2 
overexpression. This observation suggests that DNA methylation has no role in CDH1 
and KLF2 repression, mediated through EZH2 (247). Recent studies have demonstrated 
that EZH2 can directly control DNA methylation by interacting with DNMTs. This study 
concluded that these two epigenetic regulations (DNA methylation and histone 
modifications) are mechanically linked (224). 
Histone deacetylases and the DNA binding proteins associated with them could 
also be attracted to regions of methylated DNA during chromatin modification. 
Methylated DNA binding proteins, such as MBD2 also interacts with the nucleosomal 
remodeling complex (NuRD) and directs the complex to methylate DNA (256). 
Chromatin-immuno-precipitation (ChIP) coupled with meta-analysis also showed a link 
between polycomb group proteins (PcG) mediated tri- methylation on H3K27 and de 
novo DNA methylation in cancer (257). Genome-wide analysis combined with 
methylation predicted models revealed that CpG islands which are methylation prone 
have a strong association with embryonic targets of PRC2 and a subset of PRC2 targets 






MATERIALS AND METHODS 
 
3.1 Prostate cancer cell lines 
 LNCaP, DU145 and PC3 prostate cancer cell lines were purchased from ATCC 
and cultured as per ATCC recommendations as described previously (10). C-81 cells 
were kindly provided by Prof. Ming-Fong Lin (Dept. Biochemistry and Molecular 
Biology and Eppley Institute for Cancer, University of Nebraska Medical Center, Omaha, 
NE) (11). 
3.2 RNA extraction 
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) as described 
previously (43). The final RNA pellet was re-suspended in diethylpyrocarbonate 
(DEPC)-treated H2O at a concentration of 1 mg/ml and stored at -80°C until analysis. 
 3.3 Reverse Transcriptase 
 RNA (2 µg) was reverse transcribed in a final volume of 25 µl as per standard 
protocols (RT-Mix: 1.25 mM each of dNTP's; 250 ng oligo dT (Promega, Madison, WI), 
10 mM dithiothreitol, and 200 U MMLV reverse transcriptase (Invitrogen) in the MMLV 
first-strand synthesis buffer (Invitrogen). The RNA was denatured for 10 min at 65°C, 




reaction was carried out at 42°C for 1 hr and 95°C for 5 minutes. Samples were stored at 
-20°C until analysis. 
3.4 Quantitative Real Time PCR (qRT-PCR) 
qRT-PCR was performed as described previously (2) using gene specific primers 


























  PCR primers Forward (5' ) Reverse (5') 
ID4 TGCAGTGCGATATGAACGAC AGCTGCAGGTCCAGGATGTA 




DNMT1 AACCTTCACCTAGCCCCAG CTCATCCGATTTGGCTCTT 
KLF2 CGTCCTTCTCCACTTTCGCCAG 
GAAGTCCAGCACGCTGTTGA
GG                 






ID4 GACTCCCACTCAGCTCTCTT TGGAGTGGCCAGCCAATCA    
ID4 promoter Methylated (M) and Un-methylated 

















3.5 Protein Extraction 
 Total cellular proteins were prepared from cultured prostate cancer cell lines 
using M-PER (Thermo Scientific) (2). Protein samples were quantitated using the The 
Bio-Rad DC Protein Assay according to manufacturer protocol. A standard curve was 
determined using BSA and sample absorbance read at 750 nm. Samples were 
concentrated in 30 ug/ul volume and then mixed 1:1 with 2X sample buffer. 
3.6 Western Blot Analysis  
30ug of total protein, extracted from cultured prostate cancer cell lines using M-
PER was size fractionated on 4-20% SDS-polyacrylamide gel.  The SDS-gel was 
subsequently blotted onto a nitrocellulose membrane and subjected to western blot 
analysis using respective protein specific antibodies: EZH2, ID4, KLF2, and GAPDH 
(Table 4). After washing with 1x PBS, 0.5% Tween 20, the membranes were incubated 
with horseradish peroxidase (HRP) coupled secondary antibody against rabbit IgG and 
























ID4  Aviva 1:1200, 
1:200 
ID4 BioCheck 1:1000 
GAPDH Cell Signalling 1:1000, 
1:200 
EZH2 Active Motif 1:1000 
EZH2 Cell signalling 1:1000 
DNMT1 Epigentek 1:1000, 
1:150 
DNMT3A Abcam 1:1000 
RNA pol II Millipore  
IgG Millipore  
            KLF2 Millipore 1:1000 
H3Acetylation Acive motif  
H3K27Me3 Active motif 1:1000 
goat anti-rabbit Secondary 
Antibody 
Millipore 1:10000 
ICC secondary antibodies      
DyLight 594 goat anti-
mouse (red) 
Thermoscientific 1:200 
DyLight 488 goat anti-
rabbit (green) 
Thermoscientific 1:200 
DyLight 594 goat anti-
rabit (red) 
Thermoscientific 1:200 






3.7 Prostate Tissue Samples 
Formalin fixed and paraffin embedded 10um sections in duplicate from age 
matched prostate cancer (mean age 64.3+ 2.4) and benign prostate hyperplasia (mean age 
61.8 + 3.1) affixed on Leica PEN (polyethylene naphthalate) membrane coated slides 
were obtained from Cooperative Human Tissue Network (CHTN), Southern Division at 
University of Alabama at Birmingham and from Dr. Meenakshi Vij MD (Pathology), 
West Georgia Hospitals, LaGrange, GA, following appropriate IRB approvals. The 
Gleason score was available for each sample, but the pre-operative PSA values were 
unavailable. The corresponding 5um hematoxylin and eosin stained tissue sections on 
glass slides were also obtained to assess and identify the cancerous regions for laser 
capture micro dissection of tissue on Leica PEN slides. Before laser capture micro 
dissection, the sections were briefly stained with hematoxylin and compared to the 
corresponding hematoxylin/eosin stained section. The regions showing >75% cancerous 
regions or  >80% normal/ benign regions were dissected using Leica LMD6500 and 
captured in micro centrifuge tubes.   
3.8 DNA Methylation Analysis  
ID4 promoter methylation was analyzed using methylation-specific PCR (MSP) 
as described previously (2, 133). The MSP region amplified in context of the ID4 genome 
in this study has been previously investigated and well characterized in gastric (29), 
breast (132, 133) and colorectal cancers (134). Briefly, Genomic DNA from cell lines 
was isolated using DNeasy kit (Qiagen) and from laser captured sections using ZR 




sodium bisulfite-modified using EZ DNA methylation Kit (Zymo Research) and 
subjected to MSP as described previously (2, 133). Polymerase chain reactions were 
performed in a 25ul reaction using GoTaq Green master mix (12.5ul, Promega) with 
500pm each of the 5’ and 3’ primers (Table 3). Temperature conditions for PCR were as 
follows: 40 cycles of 94ºC for 30 sec, 58ºC for 45 sec and 72ºC for 30 sec, followed by 1 
cycle at 72ºC for 10 min. PCR products were separated on 1.5 % agarose gels and 
visualized using GelDoc XR+ (BioRad).  
3.9 Immuno-histochemistry (IHC) of Tissue Microarray slides  
Prostate cancer tissue microarrays were used to investigate ID4 expression in 54 
prostate cancers (n=7 for stage I, n=22 for stage II and n=25 for stage III), 11 BPH and 9 
normal prostate core biopsies (1.5mm) in duplicate (BC19014, BC19111, PRC481 and 
T192, BioMax, Inc.). The cancer stage and histological type information for each core 
biopsy was available from the manufacturer for each of the sections. The mean age 
(mean+SEM) of normal (normal + Benign) and cancer samples were 66.9+5.3 and 
71.2+4.9, respectively.  The pre-operative PSA levels for cancer samples were not 
available.  
Tissue microarray slides were de-paraffinized in xylene and re-hydrated through 
standard protocols. Antigens were retrieved by autoclaving in 0.01 M sodium citrate 
buffer pH 6.0 at 121C/20psi for 30 min. The slides were then blocked for peroxidase 
activity in 3% H2O2 (in PBST: PBS with 0.05%Tween 20) for 10 min and then blocked 
in 10% Goat serum (PBST with 1%BSA) for 2 hr at room temperature. The blocked 




slides were then washed twice with PBST for 5 min each, and then incubated with 
secondary antibody for 1 hr. The slides were washed with PBST for 5 min and stained 
with DAB for 2 min. Slides were then finally counterstained in hematoxylin and mounted 
with Immuno-mount (Thermo Scientific), examined and photo-micrographs taken using 
the Zeiss fluorescent microscope with an AxoimCam version 4.5 imaging system. 
3.10 Bisulfite Sequencing  
Direct bisulfite sequencing of the PCR product was performed as reported earlier 
(29) using ID4 specific primers as listed in table 3 and analyzed using ABI sequencer. 
3.11 Real time quantitative PCR for analysis of ID4 expression on RNA purified from 
FFPE prostate samples  
Unstained LCMD sections were obtained as above from prostate cancer regions 
that were either hypermethylated (n=10), partially methylated (n=7) and un-methylated 
benign or adjacent normal (n=9) regions. The samples were used to purify RNA using 
Qiagen FFPE RNA isolation kit.  The purified RNA was not quantifiable due to low 
volume and concentration.  To circumvent this issue, 5ul of the purified RNA was reverse 
transcribed by reverse (3’) primer of ID4 or actin real time primers.  The gene specific 
reverse transcribed RNA was then used to quantify ID4 and actin as described previously 
(2). The ∆Ct values (ID4-Ct subtracted from Actin Ct) and ∆∆Ct (fold change as 
compared to ID4 expression in benign samples) was used as a quantitative measure of 
ID4 expression. 




Student’s t-test was used to calculate differences between paired observations as 
noted in figure legends. The Cohen’s kappa coefficient was used as a measure of inter-
observer reliability for assessing ID4 staining in TMA slides. Non-parametric Kruskal-
Wallis one-way ANOVA for multiple comparisons followed by post hoc Dunn’ multiple 
comparisons test was then used to infer statistical differences between Id4 staining in 
normal/ benign and prostate cancer samples. Mann-Whitney U test, Wilcoxon signed 
rank test and unpaired t-test with Welch’s correction were used to compare methylation 
between normal (benign, ANP and normal) and cancer ordinal data sets. For all analyses, 
a P value less than 0.05 was considered significant.  Statistical analyses were performed 
with Graph Pad Prism (t-test, Mann-Whitney U test, Wilcoxon signed rank test and 
unpaired t-test with Welch’s correction). All data is expressed as mean+SEM. 
3.13 EZH2 siRNA transient transfections  
Cells were seeded in 6 well plates at 1.25x105 cells/well in 5% bovine calf serum 
(VWR) and allowed to attach overnight. The following day, cells were rinsed with serum 
free media immediately prior to transfection. Transient transfection reagent was used to 
transfect EZH2 siRNA and EZH2 siRNA control in DU145 cells according to 
manufacturer's protocol and the cells were then cultured for additional 48-72 hr.  
Subsequently, the transiently transfected cells were harvested for RNA/protein or cross 
linked with formaldehyde for Chromatin immuno-precipitation. 
3.14 Chromatin Immuno-precipitation (ChIP) Assay  
Formalin-fixed paraffin-embedded (FFPE) samples were used for ChIP based 




For this analysis, the regions showing >75% cancerous regions or more than >80% 
normal/ benign regions were dissected using Leica LMD6500 and captured in micro 
centrifuge tubes. Genomic DNA was isolated from these sections by the method of 
Fanelli et al., (260) except that tissue samples were de-paraffinized with xylene instead of 
histolemon. The chromatin extracted from tissue samples was sheared (Covaris S220), 
subjected to immuno-precipitation with  either EZH2, DNMT1, RNA POL II, 
H3Acetylation or IgG antibodies (Table 4), reverse cross linked and  subjected to 
quantitative ChIP- PCR (qChIP).  
Chromatin immuno-precipitation in cell lines was performed using the ChIP assay 
kit (Millipore, Billerica, MD) as per manufacturer’s instructions. The chromatin (total 
DNA) extracted from cells was sheared (Covaris S220), subjected to immuno-
precipitation with  respective antibodies (see above), reverse cross linked and  subjected 
to quantitative ChIP- PCR in Bio-Rad CFX.   
3.15 Immuno-cytochemistry  
Cells were grown on glass chamber slides up to 75% confluency. The slides were 
then washed with PBS (3x) and fixed in ice cold methanol for 10 min at room 
temperature and stored at -20ºC until further use.  Before use, the slides were equilibrated 
at room temperature, washed with PBS (5 min x 3), blocked with 1%BSA in PBST for 30 
min at room temp and incubated overnight (4ºC) with primary antibody (1% BSA in 
PBST). The slides were then washed in PBS and incubated with secondary antibody 
(Table 4) with fluorochrome conjugated to DyLight in 1% BSA for 1 hr at room temp in 




mounted with glycerol. Images were acquired by Zeiss fluorescence microscope through 
Axiovision software. 
Statistical Analysis   
Quantitative real time data was analyzed using the ∆∆Ct method. The ChIP data 
was analyzed against non-immune IgG used as a negative control.  Within group 
Student’s t-test was used for evaluating the statistical differences between groups. 
Normalized expression values were extracted from TCGA PRAD dataset and were 
subjected to linear regression analysis in Graph Pad Prism 5 to obtain correlation 








4.1 ID4 is silenced due to promoter hypermathylation in prostate cancer 
4. 1.1 ID4 expression and methylation in prostate cancer cell lines    
In 2009, Carey et al. demonstrated that ID4 expression is high in LNCaP cells, 
low in PC3 cells and essentially absent in DU145 cells. Lack of ID4 expression in DU145 
cells is due to promoter hyper-methylation (2). Since, LNCaP cells are less tumorigenic 
than DU145 and PC3 cells, we hypothesized that LNCaP derived cell lines, such as 
LNCaP-C33 and LNCaP-C81 which are significantly more tumorigenic, may have less 
ID4 expression due to promoter hyper-methylation. Consistent with the hypothesis, 
negligible ID4 expression was observed in the androgen independent and highly 
tumorigenic LNCaP-C81 cells (Figure. 8A).  The LNCaP-C33 cells retain partial 
androgen dependence and expressed ID4 that was significantly lower than parental 
LNCaP cells (Figure. 8A). The ID4 expression in the cell lines correlated well with its 
promoter methylation: ID4 promoter was un-methylated in LNCaP cells and was partially 
methylated in LNCaP-C33 and LNCaP-C81 cells (Figure. 8B).  The DU145 cells were 
used as a positive control for associating ID4 expression and its promoter methylation 
(2). These results demonstrated that ID4 expression is progressively lost in more 




4.1.2 ID4 expression in prostate cancer and normal prostate  
We next investigated the expression of ID4 in prostate cancer tissue.  A previous study 
reported increased ID4 expression with increasing grade of prostate cancer (141).  These 
results were inconsistent with ID4 expression in cell lines (Figure 8A), with our data 
mining (2) and other gene expression (261) studies that demonstrated decreased ID4 
expression in prostate cancer.  We, therefore, re-evaluated ID4 expression in prostate 
cancer tissues using a highly specific anti human ID4 rabbit monoclonal antibody BCH-
9/82-12-50.  The BCH-9/82-12-50 antibody was mono-specific for ID4 as demonstrated 
in Figure. 9A. A single ID4 reactive band was observed in LNCaP, PC3 and DU145 cells 
that were stably transfected with ID4 expression plasmid (DU145+ID4). No ID4 protein 
expression was observed in DU145 cells in which ID4 promoter is methylated.  These 
















Figure 8:  A: ID4 expression and methylation profile in prostate cancer. A: ID4 
expression in prostate cancer cell lines DU145, DU145+ID4, LNCaP, C33, C81 and PC3.  
ID4 expression is not observed in DU145 and C81 cells.  The androgen receptor positive 
and androgen sensitive LNCaP cells express ID4, however C81 (derivatives of LNCaP) 
are androgen receptor positive, but androgen insensitive lack ID4 expression. DU145 
cells stably transfected with ID4 expression plasmid (DU145+ID4) were used as a 
positive control for ID4 expression. B: ID4 promoter methylation in prostate cancer cell 
lines. M – methylated and U – un-methylated.  A PCR band in the “M” lane represents 
promoter methylation. A PCR band in the “U” lane represents the un-methylated 
promoter. The band in both M and U lanes represents partial methylation.  The ID4 
expression in cell lines shown in panel A corresponds with the corresponding methylation 
pattern suggesting that ID4 is epigenetically regulated. Representative data from 3 
separate experiments is shown. 
             M           U              M           U             M            U             M              U           M            U
           DU145                  LNCaP                      C33                        C81                        PC3









ID4 immuno-histochemistry was performed on normal/benign prostate (n=20, 
disease free) and prostate cancer (n=54: Stage I-III) tissue microarrays to determine their 
association with prostate cancer. ID4 expression was low to undetectable in majority of 
prostate adenocarcinoma (Figure. 9 C-H, stage I-III), whereas 100% of the normal and 
benign prostate tissue (Figure. 9A and B: 200x and 400x respectively) showed strong ID4 
expression. ID4 expression was primarily nuclear and was occasionally observed in stage 
I (Figure. 9C and D), but rarely observed in stage II and III prostate cancers (Figure. 9E-
H). Interestingly, ID4 staining was also observed in seemingly normal tubules (Figure. 
9G and H), adjacent to cancer. These results further support the observations that 

























Figure 9. ID4 expression in normal and prostate tissue samples. A: ID4 antibody 
characterization.  The left panel is the western blot analysis of ID4 expression in prostate 
cancer cell lines DU145, DU145+ID4, LNCaP and PC3. DU145+ID4 cell line was used 
as a positive control for ID4 expression, whereas parental DU145 cells were used as 




microarrays were used to investigate ID4 expression.  Please refer to materials and 
methods for TMA details and sample size. ID4 was highly expressed in normal prostate 
(A:200X and B: 400X) as seen by intense brown staining in the nuclei.  Overall, ID4 
expression decreased with increasing grade of prostate cancer (C: grade I (200X), D: 
grade I (400X), E : Grade II (200X), F: grade II (400X), G: Grade III (200x) and H: 
Grade III (400x)).  The sections are also representative of scores used to quantify staining 
intensity: A and B – score 3; C and D: score 2; E – score 0.  ID4 is mostly nuclear as seen 
by intense nuclear staining (brown, indicated by red arrow in D).  At higher stages a clear 
large nucleus with no apparent brown staining is observed (yellow arrow in D and F).  
The sections were counterstained with hematoxylin that is reflected in the blue nuclei 
observed primarily in prostate cancer sections with undetectable ID4 expression. The 
400X images in panels B, D, F and H are corresponding images of boxed regions shown 
in panels A, C, E and G (200x).  The inset in panel G is the 400x image of the region 
showing high ID4 expression in normal prostate adjacent (asterisk) to cancer (stage III). 










The intensity of staining was rated from 0 for below the level of detection to 3 for 
strongest expression (e.g. Figure. 9A was scored as 3, 9D was scored as 2, 9E was scored 
as 0) by two independent observers. The Cohen’s kappa correlation coefficient between 
the assessment of ID4 staining by these two independent observers was 0.89 (linear 
weighting) and 0.94 (quadratic weighting). Non-parametric  Kruskal-Wallis analysis 
followed by post hoc Dunn’ multiple comparisons test was used to determine statistical 
differences between ID4 staining intensity in normal prostate and prostate cancer tissue 
microarray specimens (Figure. 9). The chi square of 16.21 was less than Kruskal-Wallis 
statistic H=43.05 at p<0.0001 providing strong evidence of significant differences 
between groups (Figure. 10). The post-hoc Dunn’s test suggested a significant difference 
between the intensity of ID4 staining between normal and stage II (P=0.0023) and 
between normal and stage III (P<0.0001). Unpaired t-test with Welch’s comparison had 
the following p values: Normal versus BPH p= 0.387 (Non-significant), BPH versus 
Stage I p=0.0021 (significant), BPH versus Stage II p<0.0001 (significant) and BPH 













Figure 10: Semi-quantitative analysis of ID4 expression in normal prostate, BPH 
and prostate cancer (expressed as mean+SEM).  The intensity of staining was rated 
from 0 for below the level of detection (e.g. Figure. 9G and H) to 3 for strongest 
expression (e.g. Figure. 9A and B). The kappa correlation coefficient between the 
assessment of ID staining by two independent observers was 0.89 (linear weighting) and 
0.94 (quadratic weighting). The statistical significance was calculated with non-
parametric Kruskal-Wallis statistics followed by post-hoc Duns’s test for paired 
comparisons. The analysis demonstrates that ID4 expression is negatively correlated with 
progression of prostate cancer. The data is expressed as mean+SEM of scores given by 
each observer. Please refer to materials and methods and results section for sample size 





4.1.3 ID4 promoter is hyper-methylated in Prostate Cancer    
A strong correlation between ID4 expression and its promoter hyper-methylation 
in prostate cancer cell lines was observed (Figure. 8).  These results raised the possibility 
that the lack of ID4 expression in prostate cancer (Figure. 9) could be due to promoter 
hyper-methylation. Laser capture micro-dissection (LCMD) was used to examine ID4 
methylation in 41 prostate cancer samples, 19 benign and adjacent normal regions and 4 
benign stroma adjacent to prostate cancer regions. The available Gleason grade with 
corresponding methylation (M)/ un-methylation (U) status is summarized in Table 5. A 
PCR product using methylation specific primers (MSP) was observed in 34/41 (83%, 
ranked as 3 for statistical analysis, see below) prostate cancer samples dissected by 
LCMD confirming ID4 methylation (Table 5).  Occasionally (7 samples, 17% Table 5), a 
PCR product was also observed in the un-methylated PCR reaction suggesting that ID4 
promoter is partially un-methylated (ranked as 2 for statistical analysis) in prostate cancer 
specimens. In contrast, ID4 promoter was un-methylated in 13 out of 19 (69%, ranked as 
1 for statistical analysis) benign or benign adjacent regions. Complete promoter hyper-
methylation was observed in only one benign sample (5%), whereas partial methylation 
was observed in 5/19 (26%) benign or benign adjacent regions. ID4 promoter hyper-
methylation was also present in 3/4 (75%) benign stromal samples, as expected that is 
consistent with the lack of ID4 expression in stroma (Table 5 and Figure. 9).                
Comparison between Benign (n=19) and cancer (n=41) samples by the paired Mann-
Whitney test, Wilcoxon signed rank test and unpaired t-test with Welch’s correction 




P=0.0004 in Wilcoxon rank test and P<0.0001 in unpaired t-test with Welch’s 
correction). Due to a small sample set, the benign stromal samples (n=4) were not 




















Table 5: Status of ID4 methylation in prostate cancer tissue.
Legend:  number preceding 




“*” represents stage;         - un-methylated,         








4.1.4 ID4 promoter hyper-methylation is associated with decreased ID4 
A direct relationship between ID4 promoter methylation with ID4 expression by 
qRT-PCR was investigated in a subset of prostate cancer (n=10 each for completely 
methylated and n=7 for partially methylated prostate cancer samples) and benign prostate 
samples (n=9). As shown in Figure. 11, the ID4 expression by quantitative gene specific 
reverse transcriptase polymerase reaction on RNA purified from LCMD samples 
correlated with the corresponding ID4 promoter hyper-methylation. High ID4 expression 
was observed in normal samples (normalized to 1 in ∆∆Ct calculation) showing no ID4 
promoter methylation. In prostate cancer samples, ID4 expression was clearly dependent 
on ID4 promoter hyper-methylation: ID4 expression significantly decreased by 76 and 
222 fold (essentially un-detectable) in partially methylated and completely methylated 
prostate cancer samples respectively (Figure. 11). These analyses confirmed that ID4 









Figure 11: ID4 methylation is associated with it
top panel represents the MSP on selected prostate cancer and adjacent benign (ANP) and 
benign (Bng) samples (the numbers corresponds to the sample numbers shown in Table 
1).  A similar MSP was performed on all samples and the results are indicated in table 5.  
The bottom panel shows the quantitative real time PCR of ID4 transcript in benign, 
prostate cancer samples with partial  and complete methylation (Benign n=9; Pca partial 
methylation, n=7 (all partially methylated samples in prostate cancer) and Pca 
methylation n=10, representative shown in top panel).  The real time data is represented 
as ∆∆Ct, expressed as fold change as compared to actin and shown as mean+SEM on 
Log2 scale (y-axis). The data is normalized to ID4 expression in benign samples set to 1. 
Actin was used to normalize the data.  (*** P<0.001, t
 
 




.  The 
hyper-
Legend:        - un-methylated,     






























4.2 ID4 promoter methylation involved histone modifications 
4.2.1 Meta-Analysis of ID4 promoter methylation 
To address the mechanism involved in the epigenetic regulation of ID4, we first 
analyzed the expression of genes involved in the DNA methylation including DNMTs 
(DNMT1, DNMT3A and DNMT3B) and constituents of PRC2 (EZH2, Suz12, EED) and 
PRC1 (RING1) complex in The Cancer Genome Atlas (TCGA) (262) prostate cancer 
adenocarcinoma (PRAD) gene expression (IlluminaHiseq) database (Figure. 12A). The 
meta analysis suggested high ID4 expression in adjacent normal samples was associated 
with low EZH2, whereas inverse was observed in cancer samples, that is low ID4, but 
high EZH2 expression (Figure. 12A, right panel). The corresponding normalized EZH2 
and ID4 expression values for each sample were obtained from the TCGA dataset and 
plotted to obtain a correlation between ID4 and EZH2 (Figure. 12A, left panel). A 
significant (P<0.001) negative correlation (slope -0.8720+0.06) and correlation 
coefficient R2 = 0.3573 suggested that ID4 expression is inversely related with EZH2 
expression. These results were used to develop the hypothesis that EZH2 could be 
involved in epigenetic silencing of ID4 in prostate cancer. EZH2 forms a multimeric 
protein complexes examples with EED and catalysis tri-methylation (Me3) of lysine 27 
(K27) of histone 3 (H3). We next explored the embedded “expression” and “regulation” 
tracks using UCSC genome browser to further explore histone modifications, such as 
EZH2 mediated H3K27Me3, is observed on ID4 promoter in cells that lack ID4 




Figure 12: Meta-analysis of ID4 expression and epigenetic re
prostate cancer and cell lines.
prostate adenocarcinoma (PRAD) gene expression (IlluminaHiseq) data set was used to 
 
-programming in 







investigate expression of ID4 and genes involved in the formation of PRC2 and PRC1 
complex.  The cancer samples are represented by the blue bar and the adjacent normal by 
pink bar as indicated on the right (n=302). Left Panel – The EZH2 and ID4 normalized 
expression data for each sample in TCGA PRAD dataset (Right panel) was plotted to 
calculate the correlation between ID4 and EZH2 expression.  The results of the statistical 
analysis are shown.  A significant (P<0.001) inverse correlation (negative slope) was 
observed between EZH2 and ID4 expression B:  The custom UCSC genome browser 
tracks showing location of ID4 gene (ID4), the protein coding region (CCDS), CpG 
islands (CpG:17 and CpG196), Methylated regions in K562 cell line (K562 1 and 2), 
H3k27Me3 marks in K562 and HUVEC (bottom, scale 1 to 10) and Expression of ID4 in 
HSMM, HUVEC and KG62 cell lines (scale 1 to 100).  The source of each dataset is 
indicated above each track.  The yellow box next to 5’UTR in ID4 ref-seq track (blue) is 
the location used for methylation specific PCR, whereas the 5’ pink box (indicated by 
arrow) is the region used to investigate EZH2, H3K27Me3, DNMT1 and H3Ac 
enrichment which corresponds to H3K27me3 marks in K562 and HUVEC tracks.  C: ID4 
promoter methylation profile extracted from TCGA prostate adenocarcinoma (PRAD) 
DNA methylation (HumanMetylation450) dataset (see above).  The degree of 
methylation is indicated by blue (un-methylated) and red (Hyper-methylated) in relation 






Consistent with earlier reports, the first predicted CpG island (proximal) in ID4 
gene in UCSC genome browser was observed essentially spanning the entire length of the 
gene (CpG:196 track, Figure 12B), including proximal promoter, whereas the second 
CpG island was approximately 400bp upstream of the transcriptional start site (CpG:17 
track, Figure. 12B). Two non-ID4 expressing cell lines HUVEC and K562 (263) and ID4 
expressing cell line HSMM (Human Skeletal Muscle Myoblasts) were used to investigate 
histone modifications and respective promoter methylation in USCS genome browser. 
The rationale behind this approach was to consolidate the hypothesis that histone 
modification, in part due to EZH2 recruitment is involved in ID4 gene silencing. Active 
methylation in K562 was observed (ENCODE Hudson Alpha Methyl-seq, similar dataset 
for HUVEC was not available) around the proximal promoter which was consistent with 
the studies reported earlier in other cell lines and tissues (263). The CpG methylation 
marks in K562 cell lines were associated with increased H3K27Me3 marks (repressive), 
but no H3K4Me3 marks (active) were observed. Similar repressive H3K27Me3 marks 
were observed in the HUVEC cell lines. The HSMM (Human Skeletal Muscle 
Myoblasts) cells expressed ID4, but the methylation and Histone modification data were 
not available in the USCS genome browser at the time of this study. These results 
strongly suggested that H3K27Me3 could be associated with ID4 epigenetic inactivation 
supporting the relevance of EZH2 in this process. ID4 promoter was also methylated in 
prostate cancer, but un-methylated in adjacent normal in TCGA datasets (Figure. 12C) 




Collectively, data mining supported EZH2 dependent histone modification, specifically 
H3K27me3 on ID4 promoter. 
4.2.2 ID4 and EZH2 expression in prostate cancer cell lines 
 Previous studies (Figure. 8 and Table 5) demonstrated that ID4 promoter is hypo-
methylated in LNCaP cells, but hyper-methylated in DU145 cells (4). The C-81 cells, a 
more metastatic, androgen independent derivatives of LNCaP cells also demonstrate ID4 
promoter hyper-methylation (4). These three cells lines were used as models to 
understand the mechanism by which ID4 promoter is epigenetically regulated. Consistent 
with promoter methylation status, significantly lower ID4 transcript (Figure. 13A) and 
protein (Figure.13B) was observed in DU145 and C-81 cells as compared to LNCaP 
cells.  The EZH2 transcript and protein expression was significantly higher in DU145 
cells, but no change was observed in C81 cells as compared to LNCaP cells (Figure. 13A 
and 13B). These results are also consistent with other studies showing that EZH2 
transcript and protein expression is higher in DU145 cells as compared to LNCaP (264, 
265). DNMT1 was also expressed in all three cell lines at similar levels. These results 
suggested that ID4 promoter hyper-methylation in DU145 and C-81 and hypo-
methylation in LNCaP is not dependent on EZH2 and DNMT1 expression which 
prompted us to investigate whether these proteins are actively recruited on the ID4 





Figure 13: Expression of ID4, EZH2 and DNMT1 in prostate cancer cell lines.
Quantitative real time RT
triplicate) is normalized to GAPDH followed by fold change over LNCaP cells.  The bars 
marked with “a”, “b” and “c” corresponding to ID4, EZH2 and DNMT1 demonstrate 
statistical differences with LNCaP cells (***: P<0.001). B: Right 
analysis of DNMT1, EZH2 and ID4 expression in LNCaP, DU145 and C81 cells. 
GAPDH was used as loading control. Representative data of 3 independent experiments 
is shown. Left panel – semi
The data is normalized to GAPDH (mean+SEM, n=3, ***: P<0.001 as compared to 
LNCaP cells).   
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4.2.3 ID4 promoter is enriched with EZH2 and H3K27me3 in prostate cancer  
The promoter regions showing higher H3K27me3 marks in K562 and HUVEC 
cells (Figure. 12B) were used to investigate whether these regions are also enriched for 
EZH2 and H3K27me3 in prostate cancer cells. We designed primers to scan +38 to -400 
bp region of the ID4 promoter to investigate EZH2 and/or H3K27me3 enrichment. This 
area was selected based on the USCS genome browser dataset (Figure. 12B). The primer 
set spanning -346 to -238bp upstream of the transcriptional start site yielded a positive 
signal for EZH2 and H3K27Me3 enrichment. This region also corresponds to 
H3K27Me3 enrichment in HUVEC and K462 cell lines (Figure. 12B).  
Chromatin immuno-precipitation experiments demonstrated that ID4 promoter is 
enriched with EZH2 in C81 (% input 0.11+0.024, P<0.001) and DU145 (0.23+0.0.052, 
P<0.001) cells as compared to LNCaP cells (EZH2: 0.03+0.004). The corresponding 
H3K27Me3 enrichment was also higher in DU145, and C81 cells (0.36+0.084 and 
0.24+0.065 in C81 and DU145 respectively) as compared to LNCaP cells (0.11+0.021).  
Decreased RNA polymerase II (PolA) occupancy in C81 (0.037+0.0054) and DU145 
(0.116+0.022) as compared to LNCaP (0.36+0.061) is also consistent with ID4 
transcription (Figure. 14A) in these three cell lines. Actively transcribed genes also 
commonly exhibit increased H3 acetylation as opposed to decreased H3K27Me3. As 
expected, decreased H3 acetylation was observed in C81 (0.079+0.036, P<0.001) and 






Figure 14: Enrichment of EZH2 and histone modifications on ID4 promoter.
Enrichment of Pol II, EZH2, H3K27me3 and H3Ac on ID4 promoter in prostate cancer 
cell lines LNCaP, DU145 and C81 cells. The data is expressed (mean+SEM, n=3 in 
triplicate) as % of input. The statistical significance between enrichment (indicated by 
letters “a”, “b”, “c” and “d” corresponding to Pol II, EZH2, H3K27me3 and H3Ac 









above, but the enrichment was performed on DNA isolated from FFPE cancer/ normal 
prostate tissue by laser capture micro-dissection. The number of Benign and prostate 






















Laser capture micro-dissected prostate cancer and benign prostate tissue was used 
to further investigate EZH2 dependent histone modifications. The prostate cancer 
samples (n=5) and benign prostate tissue (n=5) were drawn from our well established 
sample set with validated ID4 promoter methylation status (4). EZH2 enrichment in 
benign prostate tissue was significantly lower (0.076+0.042) as compared to that in 
prostate cancer (0.44+0.077, P<0.001) (Figure. 14B). H3K27Me3 enrichment also 
revealed a similar profile, that is low in benign (0.31+0.071) and high enrichment in 
prostate cancer tissue (0.99+0.26, P<0.001). In contrast, ID4 promoter was highly 
enriched for the RNA polymerase II and H3 acetylation (0.55+0.078 and 0.70+0.144, 
P<0.001, respectively) in benign prostate as compared to prostate cancer (0.12+0.061 and 
0.35+0.051, respectively) (Figure. 14B). 
Together, results from prostate cancer cell lines and prostate tissue suggested that 
ID4 is regulated in part by histone modifications in an EZH2 dependent manner. 
4.2.4 Knockdown of EZH2 leads to re-expression of ID4  
To determine whether EZH2 down-regulates ID4 expression directly, we 
performed RNA interference mediated knockdown of EZH2 in DU145 cells 
(DU145+siEZH2). The immuno blot analysis in DU145 cells showed knockdown of 
EZH2 with siRNA2 to a greater extent as compared to siRNA1 and non-specific siRNA 
(ns-siRNA) 72 hr after transfection (Figure. 15A). Based on these results, all subsequent 
studies were performed with EZH2 siRNA2. The results from quantitative real-time PCR 
revealed a significant increase in the expression of ID4 and KLF2 (Figure. 15B) in 




used as a positive control which is down-regulated by EZH2 (248). The immuno-
fluorescence analysis also revealed increased ID4 expression in DU145+siEZH2 as 
compared to non-silencing controls (Figure. 16 C4). Knockdown of EZH2 also resulted 
in decreased EZH2 specific H3k27me3 repressive marks with a corresponding increase in 
the enrichment of transcriptionally active H3 acetylation marks and RNA polymerase II 
on ID4 promoter (Figure. 17A).  
 
 
Figure 15: Effect of EZH2 silencing on ID4 expression. A: Two different siRNAs 
(siRNA1 and siRNA2) were used to transiently knock down EZH2 in DU145 cells 
followed by western blot analysis of EZH2, ID4 and KLF2 (used as a positive control for 
EZH2 dependent down-regulated gene).  Increase in ID4 expression with greater EZH2 
knock down was observed with siRNA2 that was used for all subsequent studies. 
Representative western blot is shown. B: Real time quantitative RT-PCR analysis of 
corresponding gene expression following EZH2 knockdown by siRNA2.  The data is 




Figure 16: Immuno-cytochemical analysis of ID4 expres
mediated knockdown of EZH2 in DU145 cells (x200 magnification). ID4 expression is in 
red and the nuclei in Blue (DAPI). C.1 and C.4 are merged images of Blue (Nuclei, C.2 
and C.5) and Red (ID4, C.3 and C.6). C.1, C.2 and C.3 are DU145
non-specific siRNA (DU145+NS). Panels C.4, C.5 and C.6 are DU145 cells transfected 







sion following siRNA2 











Figure 17: Association between EZH2 and DNMT1 on ID4 promoter.  A: Enrichment 
of EZH2, H3K27me3, H3Ac and DNMT1 on ID4 and KLF2 promoters following EZH2 
knockdown in DU145 cells. The data is expressed (mean+SEM, n=3 in triplicate) fold 
change of % input as compared to DU145 cells transfected with non-specific EZH2 
siRNA. B: Western blot analysis of DNMT1 expression in DU145 cells with non-
silencing siRNA or with EZH2 si-RNA2 (siEZH2). Representative of 3 blots is shown. 
C: Methylation specific PCR (MSP) on ID4 promoter following knockdown of EZH2 in 
DU145 cells. A band in “M” lane represents methylation of ID4 promoter where as a 






EZH2 physically interacts with and recruits DNA methyl-transferases DNMT1, 
3A and 3B to promote methylation and  establish stable repressive chromatin structures 
(40), suggesting that histone modifications acts upstream  of methylation and/or its 
initiation.  Previous studies from our laboratory have shown that treatment of DU145 
cells with 5-azacitidine leads to re-expression of ID4 (2). 5-azacitidine promotes 
proteosomal degradation specifically of DNMT1 (266) suggesting that ID4 promoter 
hyper-methylation in DU145 cells is in part mediated by DNMT1. Based on these 
studies, we next investigated whether DNMT1 is also recruited on ID4 promoter in an 
EZH2 dependent manner. Results from chromatin immuno precipitation experiments 
suggested significantly decreased DNMT1 enrichment on ID4 promoter in 
DU145+siEZH2 as compared to DU145+siNS cells (Figure. 17B). Surprisingly, 
enrichment of DNMT1 on KLF2 promoter was not significantly different between 
DU145+siEZH2 and DU145+siNS cells. KLF2 promoter is also an EZH2 target gene in 
many cancers (248) and recently shown to be hyper-methylated by DNMT1 in 
endothelial cells (267). The reduction in DNMT1 enrichment on ID4 promoter could be 
due to its decreased expression following EZH2 knockdown.  In order to confirm this, we 
investigated the expression of DNMT1 in DU145+siEZH2 and DU145+siNS cells 
(Figure. 17B). Surprisingly, the DNMT1 levels were similar between DU145+siEZH2 
and DU145+siNS cells. These results suggested that the reduced DNMT1 recruitment on 
ID4 promoter was due to decreased EZH2 recruitment and not due to decreased 
expression of DNMT1. Next, we investigated whether increased ID4 expression in 




methylation. The methylation specific PCR on ID4 promoter using bisulfite treated DNA 
from DU145+siEZH2 cells reveled decreased promoter methylation as compared to 
DU145+siNS (Figure. 17C). Together, these results suggested that EZH2 silencing leads 
to decreased DNMT1 recruitment resulting in ID4 promoter hypo-methylation. 
4.2.5 Knockdown of EZH2 results in Hypo-methylation of ID4 promoter 
Finally, direct bisulfite sequencing was performed on DU145+siNS, 
DU145+siEZH2 and LNCaP cells. The sequence of the region amplified MSP primers 
(the sequencing primers flanked the MSP region shown in Figure. 8B) confirmed, as 
expected that the CpG islands in LNCaP cells were hypo-methylated (conversion of “C” 
to “T” by bisulfite reaction), but were hyper-methylated in DU145+siNS (no conversion 
of “C” due to methylation). Partial conversion of “C” to ”T” was observed in 
DU145+siEZH2 cells.  Sequence alignments allowed us identify critical CpG islands 
(indicated by arrow heads (Figure. 18) that were hypo-methylated in DU145+siEZH2 
cells resulting in ID4 expression (Figure. 16). These results led us to conclude that EZH2 
recruitment promotes ID4 hyper-methylation through a complex process involving 
H3K27me3 and DNMT1. 
  
 
Figure 18: Bisulfite sequence of MSP/ USP region of ID4 promoter.  
The Genomic sequence is indicated at the top (
site).  BSP: The predicted sequence after bisulfite conversion. The consensus sequences 
from LNCaP, DU145+siNS (DU+siNS), DU145+siEZH2 (DU+siEZ) are represented.  
The methylated Cytosine (C, red) and un
(T, Green) after bisulfite conversion are indicated. Polymorphism was observed at CpG 
islands in DU145+siEZH2 (C/T) hence two sequences are displayed.  The read from two 
 
-192 to -35 bp from transcriptional start 








representative sequences is shown. The arrow heads at the bottom indicates possible site 





                                                 DISCUSSION 
5.1 ID4 is epigenetically silenced due to promoter hyper-methylation 
In this report we demonstrate that ID4 expression is attenuated in prostate cancer 
due to promoter hyper-methylation. This study strengthens previous reports (2, 48, 154) 
which provided direct evidence that ID4 acts as a tumor suppressor in prostate cancer. 
The tumor suppressor role of ID4 appears to be unique as compared to other members of 
the ID gene family (ID1, ID2 and ID3) that may act as oncogenes or co-operating 
oncogenes in many cancers (96, 101, 109).  
A recent report suggested a positive association between ID4 expression and 
prostate cancer metastasis (141). On the contrary, we provide multiple lines of evidence 
that demonstrate decreased ID4 expression in prostate cancer. First, in LNCaP cell line 
based prostate cancer progression model ID4 transcript is decreased from androgen 
dependent LNCaP cells to androgen independent LNCaP-C81 cells, with an intermediate 
expression observed in LNCaP-C-33 cells. Second, ID4 protein expression is 
significantly decreased and, in most cases, undetectable in advanced stages of prostate 
cancer as detected by a highly specific rabbit monoclonal antibody. Moreover, multiple 
microarray studies ((261) and summarized in (2)) on clinically well-defined prostate 
cancer samples and analysis of a subset of clinical samples in our study also 




expression in prostate cancer is observed at both transcript and protein level. At the 
mechanistic level, the transcriptional inactivation of ID4 is associated with aberrant 
promoter methylation in prostate cancer cell lines and tissue samples as demonstrated in 
this study and confirmed by others (17). Our results are, therefore, consistent with the 
epigenetic silencing of ID4 due to promoter hyper-methylation in cancers: T-/natural 
killer acute lymphoblastic leukemia (19), gastric (29), breast (133) colorectal (134) and 
prostate cancer (17). 
The silencing of ID4 in cancers raises an important question: what is the normal 
physiological function of ID4 in at least those tissues which upon transformation leads to 
its loss of expression such as the prostate? Studies conducted by Carey et al. (2) provided 
some answers at the mechanistic level: 1) androgens up-regulate ID4 expression in 
normal prostate epithelial cell (PrEC) and 2) ectopic ID4 expression in androgen receptor 
negative DU145 cells leads to increased E-cadherin expression and decreased cell 
proliferation due to an S-phase arrest, increased expression of cyclin dependent kinase 
inhibitors p21 and p27, and most importantly, restoration of androgen receptor 
expression. The increase in the transcript of p27, p21, E-cadherin and androgen receptor 
in DU145 cells suggests that ID4 over-expression modifies intracellular transcriptional 
pathways possibly through complex protein-protein interactions leading to restoration of 
transcriptional networks that are in general tumor-suppressive. Induction of ID4 by 
androgens in normal cells and restoration of androgen receptor in DU145 cells also 




by which AR becomes oncogenic could be due to its inability to trans-activate tumor 
suppressors such as ID4 due to promoter hyper-methylation.  
The HLH domain between ID4 and its other family members (ID1, ID2 and ID3) 
is highly conserved, thus, supporting its role as a negative regulator of bHLH 
transcription factors (268). The tumor-promoting properties of ID1, ID2 and ID3 are at 
least partially shared by ID4 also: ID4 has been shown to promote neoplastic 
transformation/growth. Increased ID4 expression is observed in acute lymphoblastic 
leukemia due to a t(6;14)(p22;q32) translocation (135). ID4 expression is also associated 
with proliferation and invasiveness (138) in rat mammary gland carcinoma. Moreover, in 
breast cancer cells, ID4 and the tumor suppressor BRCA1 exist in a negative feedback 
loop (144, 145, 269). But studies have also demonstrated epigenetic silencing of ID4 in 
breast cancer (132, 133). Thus, even in cancers arising from the same organ such as the 
breast, ID4 may act as both tumor suppressor and tumor promoter (132, 133, 138, 144, 
145, 269). Evidence suggests that ID4 may share some functions with its family 
members, but emerging data supports the role of ID4 as a tumor suppressor. We speculate 
that ID4 may have unique bHLH or non-bHLH interaction partners that could largely 
define its tumor-promoting versus tumor suppressor functions. Support for this 
mechanism is based on the evidence that interactions of ID2 with Rb (270, 271) and 
polycystins (272), ID1 and ID3 with Ets (273) transcription factors largely contribute to 
their oncogenic potential by releasing cell cycle blockade at multiple levels (274). 
Although all these mechanism are largely tumor-promoting, but similar tumor-




5. 2 Epigenetic silencing of ID4 due to association between DNA methylation and 
histone modification 
The data presented here supports an EZH2 dependent epigenetic silencing of ID4 in 
prostate cancer. This conclusion is particularly compelling when the experimental data 
(cell line and clinical studies) is compared to the meta-analysis of ID4 promoter (UCSC 
genome browser) and remarkable mutually exclusive expression profile of EZH2 and ID4 
in prostate cancer (TCGA datasets and experimental evidence). A number of studies 
support the role of EZH2 as an oncogene in prostate cancer that is typically associated 
with increased risk of metastasis and recurrence (42, 43, 275). Knockdown of EZH2 in 
prostate cancer cell lines results in decreased cellular growth and invasion (265, 276-
278). EZH2 mediated transcriptional repression of putative tumor suppressors such as E-
cadherin (279) via increased H3K27Me3  is dependent on SET domain that in addition to 
methyl transferase activity also requires histone de-acetylase activity, possibly through 
recruitment of  HDAC2 by EZH2,  itself a component of PRC2 complex (280). Such a 
co-operative histone modification is clearly observed on ID4 promoter where increased 
EZH2 dependent histone methylation is associated with decreased histone acetylation, 
further contributing to the repressive histone marks.  
ID4 expression is also tightly controlled by epigenetic mechanisms during 
oligodendrocyte differentiation by PRMT5, a type II protein arginine methyltransferase.   
PRMT5 associates with ID4 CpG islands and is required for maintaining its methylation 




In prostate cancer cells PRMT5 expression is primarily cytoplasmic and promotes 
growth. In contrast, PRMT5 is nuclear in benign prostate epithelial cells where it inhibits 
growth (281). Thus, PRMT5 localization (predominantly cytoplasmic) in prostate cancer 
does not correspond with its role in ID4 methylation or association with CpG islands, 
which as one would expect to be in the nucleus. However, direct evidence demonstrating 
the ID4 gene expression is independent of PRMT5 in prostate cancer remains to be 
investigated. Re-expression of ID4 by silencing EZH2 suggests that EZH2 dependent 
H3K27me3 could be an early event in establishing this histone code that may recruit 
DNA methyl- transferases to promote DNA methylation. We and others have 
demonstrated that inhibition of DNMT1 by 5- Azacitidine treatment also promotes ID4 
expression in DU145 cells (2, 17), clearly suggesting that these two processes are inter-
related. Indeed, studies have shown that treatment of cells with 5-Aza results in removal 
of H3K27me3 marks without altering the expression of EZH2 or other histone methyl 
transferases (282). Furthermore, we observed that methyl transferases such as EZH2 were 
present in the same region as DNMT1 on ID4 promoter, possibly in the same protein 
complex (40, 283, 284). Thus, interfering with either EZH2 (siRNA) or DNMT1 (5-Aza) 
could de-stabilize the epigenetic mark resulting in increased ID4 expression. Thus, 
increased EZH2 expression and its subsequent recruitment appears to be the primary 
mechanism involved in epigenetic silencing of ID4 in prostate cancer. The role of other 
co-operating proteins within PRC1 and PRC2 cannot be ruled out as their expression/ 
recruitment could alter ID4 methylation/ histone modifications. Lack of a significant 




recruitment of protein complexes takes precedence over expression in epigenetic 
modifications at least in context of ID4.  This is partly reflected in the TCGA expression 
profile where the expression of other PRC1/2 complex proteins does not change to the 
extent as compared to EZH2 in normal prostate and prostate cancer. Evidence that 
assembly and not expression of PRC1/2 complex proteins is dependent on recruitment 
EZH2 as the initial step is also apparent from studies indicating that the expression of 
BM1-1, SIRT-1, DNMT1 and DNMT3b is not associated with prostate cancer (285). 
Whether the EZH2-DNMT mechanism is specific to prostate cancer or a more general 
pro-cancer pathway involved in ID4 gene silencing remains to be investigated. It is also 
possible that ID4 gene regulation may be distinct in cancer cells versus cell undergoing 
proliferation/ differentiation that require stage specific accessibility to ID4 transcriptional 
regulators such as those involving sp1/ bHLH/ hormones through alternate mechanism, 







Epigenetic alterations have now emerged as major contributors to prostate cancer 
disease imitation and progression. The detailed investigation of the molecular 
mechanisms involved in regulating these epigenetic changes will remain the major focus 
of current and future research. Our results demonstrate that ID4 expression is decreased 
in prostate cancer due to promoter hyper-methylation. Our results, in general, agree with 
the majority of results that support the role of ID4 as a tumor suppressor due to epigenetic 
inactivation in other cancers. The EZH2-DNMT dependent mechanism, at least in 
prostate cancer, suggest that targeting this pathway through specific inhibitors resulting in 
general epigenetic re-programming, including up-regulation of ID4, could be a strong 
therapeutic strategy. Previous studies have shown that ectopic ID4 expression alone 
results in cell cycle arrest (2), induction of apoptosis and senescence (286), activation of 
p53 (154) and increased sensitivity to chemo-therapeutics (286). Thus, strategies that can 
either specifically re-program ID4 promoter or target ID4 dependent downstream 
pathways are strong therapeutic approaches that needs to be explored. Contrary to these 
observations, studies have also demonstrated pro-tumor function of ID4 that is consistent 
with its other family members ID1, ID2 and ID3. In this regard, studies from breast 




ID4. We speculate that these opposing roles of ID4, sometimes in the cancers originating 
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